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Abstract
An important event during infection by retroviruses such as human immunodeficiency virus
type 1 (HIV-1) is the permanent integration of the viral genome into the host genome. This
event leads to life-long infection and is accompanied by a period of quiescence/latency ranging
from a few years to >10 years where HIV-1 expression is barely detectable or undetectable.
Despite the use of combination antiretroviral therapy (cART) which controls HIV-1 infection,
quiescent/latent virus presents a major obstacle towards a functional cure. Integration site
location in the genome is thought to contribute to latent infections and has the potential to
confound anti-latency treatments, necessitating a greater understanding of the effects of
integration site location on latency.
To examine the global preference for integration location, we performed an extensive
bioinformatics analysis on the integration site profile of HIV-1 and other retroviruses. We
found that HIV-1 integration sites and that of other retroviruses are enriched in and/or near
non-B DNA motifs. Non-B DNA are secondary structures in our genome formed by specific
nucleotide sequences that exhibit non-canonical DNA base pairing. We demonstrated a strong
correlation between integration sites in and near guanine-quadruplex (G4) motifs, a type of
non-B DNA associated with transcriptional silencing, and reactivation of latent proviruses with
latency reversal agents. Additionally, integration site studies have focused on HIV-1 subtype
B infections; however, infections with other subtypes exist worldwide. A comparative analysis
of 62 infected individuals with different HIV-1 subtypes showed significant differences in the
integration site profiles between different subtypes, which was further altered by cART.
Finally, we examined HIV-1 integration site profiles in anatomical sites and showed distinct
integration profiles from peripheral blood, brain, and the gastrointestinal tract.
Overall, our findings identified similarities and differences in the integration site profiles
among evolutionarily diverse retroviruses. Notably, we have implicated non-B DNA as a new
factor that influences integration site targeting and may play an important role in the
establishment of HIV-1 latency and/or disease progression.
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Chapter 1

1

Introduction

Viruses are obligate parasitic microganisms that can hijack host cellular pathways and
machineries for their replication and persistence; retroviruses are no exception. The
Retroviridae or retrovirus family encompass a diverse group of small enveloped viruses
capable of spreading and causing severe diseases. All retroviruses have a positive sense
single-stranded ribonucleic acid (RNA) genome ranging from 7 to 12 kilobases (kb) in size
1

. This family of viruses is divided into 7 genera that include: the alpha-, beta-, gamma-,

delta-, epsilon- retroviruses, the spumavirus and the lentivirus 1,2. Retroviruses are further
classified into 2 categories comprising the simple and complex retroviruses. The main
difference between the simple and complex retroviruses lies in their genomic organization
1

. More specifically, simple and complex retroviruses encode for three major polyprotein

genes: the group specific antigen (gag), the polymerase (pol), and the envelope (env) gene
1,2

. However, contrary to the simple retroviruses, the complex retroviruses code for other

regulatory and accessory genes in addition to the three major genes 1,2. Table 1. 1 gives a
list of identified retrovirus genera with examples of species for each. Retroviruses have a
unique life cycle that involves conversion of their genomic RNA into linear doublestranded deoxyribonucleic acid (DNA) and integration of the double-stranded DNA into
the chromosomal host DNA

1,2

. These steps of their life cycle are hallmarks of the

Retroviridae family. Additionally, the ability of retroviruses to permanently integrate their
viral DNA into the chromosomal host DNA allows these viruses to maintain a persistent
life-long infection within diverse vertebrate organisms 1. One of the most studied and
clinically prevalent retroviruses is the human immunodeficiency virus (HIV). HIV is a
complex retrovirus belonging to the lentivirus genus. Lentiviruses represent a genus of
viruses that cause slow and chronic disease. HIV is the causative agent of Acquired
Immunodeficiency Syndrome (AIDS) a chronic disease characterized by the depletion of
CD4+ T-lymphocytes (CD4+ T cells) 3.

2

Table 1.1: List of retrovirus genera (adapted from reference 2 ).

Genus Name

Alpharetrovirus

Betaretrovirus

Gammaretrovirus

Deltaretrovirus

Epsilonretrovirus

Spumavirus

Lentivirus

Species Examples

Genome
Characteristic

Avian sarcoma leukosis virus
Avian myeloblastosis virus
Rous Sarcoma virus

Simple

Mason-Pfizer monkey virus
Mouse mammary tumor virus
Langur virus

Simple

Murine leukemia virus
Moloney murine sarcoma virus
Feline leukemia virus

Simple

Human T-lymphotropic virus 1
Human T-lymphotropic virus 2
Bovine leukemia virus

Complex

Walleye epidermal hyperplasia virus 1
Walleye epidermal hyperplasia virus 2
Walleye dermal sarcoma virus

Complex

Feline foamy virus
Equine foamy virus
Bovine foamy virus

Complex

Human immunodeficiency virus type 1
Human immunodeficiency virus type 2
Simian immunodeficiency virus

Complex

3

Two types of HIV have been identified and are classified as HIV type 1 (HIV-1) and HIV
type 2 (HIV-2) 3,4. Both HIV-1 and HIV-2 share a similar genomic organization but differ
in their pathogenicity. In fact, HIV-1 is the main agent of the HIV/AIDS pandemic while
HIV-2 infection is confined to regions in Western and Central Africa 3. Currently, more
than 36 million individuals are infected with HIV-1 worldwide with approximately 2
million new infections occurring annually 5. In this thesis, the focus will be on HIV-1
infection.
Since the discovery of HIV-1 in the early 1980’s

3,6

the scientific community has made

great efforts towards developing effective therapeutic drugs that control HIV-1 infections.
However, advances in the development of combination antiretroviral therapy (cART) can
only help control HIV-1 replication in infected individuals and fail to eradicate the virus 7.
Early during infection (within hours to days), HIV-1 may actively replicate leading to
productive infection while in some cases, HIV-1 can become quiescent/latent

8,9,10,11

. HIV-

1 viral latency is characterized by the low expression levels of viral transcripts (which is
undetectable by most sensitive assays) or no expression of viral transcripts 12. Therefore,
in this thesis, HIV-1 latency is defined as having undetectable and no expression of viral
transcripts/proteins.
Latent viruses can remain inactive for years without producing viral proteins. This allows
latently infected cells to become undetectable by the immune system and escape cytopathic
effect

12

. Additionally, cART is only effective against replicating viruses and are

ineffective against latent viruses

12

. However, latent viruses can replicate and produce

infectious particles when cART treatment is discontinued

13,14

. Thus, a cure for HIV-1

infection requires the complete elimination of latently-infected cells. Latently infected cells
present a challenge for HIV-1/AIDS eradication, which remains an incurable disease and
a major public health concern worldwide. Previous studies reported an association between
HIV-1 integration sites in the human genome and disease persistence/latency, but the
mechanisms underlying this association are unclear 15. Therefore, this thesis investigates
the integration site selection profile primarily in the context of HIV-1 infection and how

4

integration site selection in the genome may contribute to a persistent live-long infection
of the virus.

1.1

A brief history of HIV-1/AIDS

In the early 1980s, cases of a new human epidemic began to emerge. Infected individuals
presented unusual symptoms of immune dysfunction 16. In 1981, AIDS was recognized by
the scientific community. AIDS manifested itself with a rapid decrease in the CD4+ T cell
count, usually below 200 cells/mm3

17

. During this stage, individuals succumbed to

otherwise rare opportunistic infections and unusual cancers. Most notably, the same type
of T cells are targeted by the human T-lymphotropic virus 1 (HTLV-1). HTLV-1 was
isolated in 1980 by Dr. Robert Gallo and was reported as the first pathogenic human
retrovirus 18. However, HTLV-1 transforms CD4+ T cells into T-cell leukemia and does
not cause depletion of CD4+ T cells. This suggested that a new, unknown retrovirus was
responsible for the epidemic seen at the time. In 1983, Dr. Luc Montagnier and his
colleagues at the Pasteur Institute isolated the virus from the lymph nodes of patients with
acute lymphadenopathy 6 . The virus was first known at the time as the lymphoadenopathyassociated virus and was suspected to have been the cause of AIDS. One year later, Dr.
Gallo and his collaborators at the National Institute of Health confirmed this new virus has
been the causative agent of AIDS 19,20 . In 1986, the newly discover human retrovirus was
officially termed HIV-1 21.

1.2

The human immunodeficiency virus type 1 (HIV-1)

Following the discovery of HIV-1, great progress had been made in understanding more
about HIV-1. Notably, these advances include a detailed understanding of the HIV-1
modes of transmission, pathogenesis, structure, complete sequencing of the HIV-1
genome and isolation of different HIV-1 subtypes.

1.2.1 Classification of HIV-1 groups and subtypes
With the rise of the polymerase chain reaction (PCR), amplification of viral genomes was
made possible. This was followed by advances in genome sequencing that further helped
establish the sequences of diverse HIV-1 isolates throughout the world 3. The identified

5

HIV-1 isolates/strains are currently divided into three major groups. This include group M
(“M” stands for main), group N (“N” stands for non M or O), group O (“O” stands for
outlier) 3,22,23. A new isolate that is divergent from the major groups has also been identified
and is classified as group “P” 24 . The HIV-1 M group which constitutes 95% of all isolated
HIV-1 strains is further subdivided into 9 distinct clades or subtypes

25

. The M group

subtypes are designated A, B, C, D, F, G, H, J, and K. Viruses of the M group dominate
most HIV-1 infections worldwide. Subtypes within the N group have not been fully
determined. Nevertheless, only a few isolates of the N group have been sequenced 26. On
the other hand, no subtypes have been defined for group O and P. Additionally,
recombinant forms of HIV-1 have also been isolated. Recombinant forms occur as a result
of a recombination event between the genome of identical subtypes or different subtypes.
These recombinant viruses are known as circulating recombinant forms (CRFs). As of
2018, more than 90 CRFs have been characterized 26.

1.2.2 HIV-1 virion structure and composition
The HIV-1 virion has an average diameter of 100 nm with a spherical to conical shape 4.
Each virion is surrounded by a host derived envelope membrane

23

(Figure 1.1). The

envelope membrane anchors surface glycoproteins (gp120 and gp41) which aid viral entry
4,23

. The envelope membrane is further surrounded by an inner layer of the viral matrix

(MA) proteins. Additionally, the envelope encases a cone-shaped core composed of the
capsid (CA) proteins. The conical core capsid harbors the copies of viral RNA genomes
and the nucleocapsid (NC) protein that form a complex with the viral RNA genomes 3,4,23,27.
The virion also encloses three essential viral enzymes:

reverse transcriptase (RT),

integrase (IN) and protease (PR)23. Accessory and regulatory proteins are also present
within the virion. These include viral infectivity factor (Vif), virus protein R (Vpr), viral
protein U (Vpu), negative regulator factor (Nef), and RNA splicing-regulator (Rev)
proteins 3.

6

Figure 1.1

Figure 1.1: Illustration of the HIV-1 virion (adapted from reference 27).
).
The size of the HIV-1 virion is ~100nm in diameter and is enveloped by a host-derived
lipid membrane. The gp120-gp41 glycoprotein complexes are embedded in the lipid
).
membrane. The matrix proteins line the inner membrane of the envelope. The capsids make
).
up the conical core which contains the two single-stranded RNA genomes. The viral RNA
genomes are surrounded by nucleocapsid proteins. Functional and accessory proteins such
as integrase (IN), reverse transcriptase (RT), protease (PR), Vpr, Vif, Nef, and Vpu as well
as host proteins are packaged into the virion.

7

1.2.3 HIV-1 genomic organization and gene functions
The HIV-1 genome consists of positive sense single-stranded RNA. The size of the HIV1RNA molecules are about 9.2 kb. The HIV-1 genome contains 9 genes that encode 15
viral proteins. Figure 1.2 shows a description of the HIV-1 genome.
The gag gene produces a polyprotein (Pr55Gag) that encodes all structural proteins and is
proteolytically cleaved into the capsid (CA/p24), the matrix (MA/p17), the nucleocapsid
(NC/p7) and the particle release protein (p6) 28. The pol gene codes for 3 viral enzymes
that are essential for viral replication. These enzymes include the RT, IN and PR. RT
(p66/p51) is responsible for the reverse transcription of the viral RNA genome into DNA
28

. IN (p32) mediates the integration of the reverse transcribed viral DNA into the host

DNA29. PR (p10) enzyme is essential for the cleavage of the polyprotein during maturation
of the viral particle 28. The env gene encodes the viral envelope glycoproteins 120 and 41
(gp120 and gp41). Both glycoproteins mediate viral entry into the host cell. Gp120 is the
surface (SU) glycoprotein that mediates viral attachment to the target cell

28

. Gp41 is the

transmembrane (TM) glycoprotein that anchors fusion of the viral and cell membrane 28.
These two proteins arise from the glycosylation and proteolytic cleavage of the full-length
gp160.
As a complex retrovirus, HIV-1 encodes 6 other regulatory and accessory genes in addition
to the three major genes. The regulatory genes include transactivation of transcription (tat)
and RNA splicing-regulator (rev). The Tat protein induces an increase in transcription and
promotes full-length elongation of the viral transcripts 30,31. The Rev protein helps facilitate
the transport of unspliced and incompletely spliced messenger RNAs from the nucleus to
the cytoplasm

32

. The accessory genes of HIV-1 are the viral infectivity factor (vif), the

virus protein R (vpr), the virus protein U (vpu) and the negative regulator factor (nef).
Examples of some of the functions of each accessory protein are described as follows: Vif
(p23) is the accessory protein that modulates and enhances HIV-1 infectivity in certain
target cells such as lymphocytes and macrophages 33. Vpr (p15) facilitates the transport of
the viral DNA in the nucleus for integration 34–36. Vpr also promotes cell cycle arrest at the
G2 phase

37

. The Vpu (p16) protein enhances viral release during budding

mediates degradation of CD4 through ubiquitination 39.

38

and also
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Figure 1.2

Figure 1.2: HIV-1 proviral DNA structure (adapted from reference 27).
The HIV-1 genome has 9 open reading frames that code for 15 viral proteins and is flanked by the long terminal repeat (LTR) at both
5’ and 3’ ends.
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Degradation of CD4 helps release the Env protein from CD4-env complex in the
endoplasmic reticulum (ER). Nef (p27) mediates down regulation of cell surface
expression of CD4 and the major histocompatibility complex class I (MHC I) 40,41. Nef is
also involved in modulating HIV-1 replication and enhances infectivity of the virion 42.
Furthermore, the integrated proviral DNA is flanked at both 5’and 3’ends of the viral
genome by the long terminal repeat (LTR) region. The LTR regions contain promoter sites,
enhancers sites, transcription termination sites/polyadenylation signal and other regulatory
signals that interact with the host transcriptional machinery. Each of the LTR sequences
is composed of 3 regions that include the U3 (3’ unique), R (repeated sequence) and the
U5 (5’unique) region

43

. More specifically, the 5’LTR contains binding sites for cellular

transcription factors, enhancers and cellular RNA polymerase 28. The 5’ LTR region also
contains the promoter binding site for the HIV-1 Tat protein
packaging signal sequence denoted as the ψ (Psi) signal

44

28

as well as the viral RNA

. On the other end, the 3’LTR

acts as a transcription termination and polyadenylation site 45,46.

1.2.4

HIV-1 replication and disease progression

HIV-1 infection starts with the attachment of the virion to its target cell and subsequent
fusion of the viral and target cell membrane (Figure 1.3)

47

. The viral envelope, that

harbors the gp120 and gp41 heterodimer, mediates viral entry into the host cell. Viral entry
is initiated by the surface envelope glycoprotein gp120 through binding to its cellular
receptor CD4 48–50. Specifically, gp120 binds the CD4 receptor via its C4 domain 51. Host
cells that are CD4 positive such as helper T cells, macrophages, dendritic cells, microglial
cells and astrocytes are targets for HIV-1 infection. Following this initial attachment, the
gp120 undergoes a conformational change exposing a conserved region within the third
variable loop in the gp120

52

. This allows binding of gp120 to its co-receptor. The co-

receptors for HIV-1 infection are chemokine receptor type 5 (CCR5) or chemokine
receptor type 4 (CXCR4) 53. The binding of gp120 to CD4 and to the co-receptor induces
an additional structural change in gp120 with a subsequent change in gp41 conformation.
These changes in gp41 conformation lead to its insertion into the cell membrane via it’s Nterminal fusion peptide, and fusion of the host cell membrane and viral envelope occurs 54.
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Figure 1.3

Figure 1.3: HIV-1 replication cycle (adapted from reference 47).
HIV-1
infection begins with attachment of the gp120 and gp41 to the CD4 cell surface
).
membrane receptor and the CXCR4 or CCR5 co-receptor, respectively. Following entry
into cells and uncoating of the core shell, the viral RNA is reverse transcribed into the
double-stranded viral cDNA. The viral cDNA interacts with other host and viral proteins
forming the pre-integration complex. The pre-integration complex then gets imported into
the nucleus. The viral integrase enzyme facilitates the integration of the viral DNA into the
host DNA. Following integration, more viral RNAs are transcribed and are translated into
viral proteins. Viral RNAs and viral proteins assemble at the plasma membrane. The
immature virions bud from the cell. The viral polyproteins are proteolytically cleaved
generating mature virions that are able to infect new cells.
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Following this fusion event, the viral core is translocated into the cytoplasm with a
subsequent uncoating of the capsid and release of the viral RNA genome and proteins in
the cytoplasm. In the cytoplasm, the viral RNA is reverse transcribed into a doublestranded complimentary DNA (cDNA) via RT activity. The viral cDNA then associates
with the IN and several viral and host proteins forming the pre-integration complex 55,56 .
After the formation of the pre-integration complex, it is actively transported into the
nucleus through microtubules 57 and microfilaments 58. In the nucleus, the viral DNA gets
incorporated into the host cell’s genome via the viral IN in a process called integration.
The integration process will be further described in section 1.4.1. The permanently
integrated viral DNA is referred to as a provirus. Once integrated, the proviral DNA can
become actively expressed for the production of viral progeny or remain silent during latent
infection. All viral genes are transcribed by the host RNA polymerase II and initiate in the
LTR. Completely spliced messenger RNAs of the tat and rev gene are expressed during
the first stage of infection. This event is followed by the expression of incompletely spliced
messenger RNAs encoding the env, vpr, vif and vpu genes 59.
Later during infection, full-length unspliced messenger RNAs encoding the full-length
viral RNA and the Gag-Pol polyprotein are transcribed. Transport of unspliced and
incompletely spliced transcripts into the cytoplasm is mediated by the Rev protein

32,59

.

Lastly, newly generated viral particles bud from the host cell membrane followed by
maturation of the particles due to PR cleavage of the Gag and Gag-Pol polyproteins. Mature
viral particles can now infect other cells.

1.2.5

The course of HIV-1 infection

The immunological and virological factors used to determine HIV-1 progression in
infected individuals are the CD4+ T-cell count and the RNA viral load in the plasma

60

.

HIV-1 disease progression can be divided into 3 stages. These include: 1) acute infection,
2) chronic asymptomatic stage, and 3) AIDS 61,62. These stages are usually seen in patients
not receiving anti-retroviral treatment

17

. Acute infection is characterized by a drastic

increase in the level of circulating virus and a decrease in CD4+ T-cell count in the blood
and peripheral lymphoid tissues. The acute stage usually occurs during the first 2-10 weeks

12

of infection 17. Following this period of primary infection, there is a decline in viral load
and an increase in CD4+ T-cells

17

. The decline in viral load occurs due to self-limiting

infection and an elevated immune response/rise in CD8+ T-lymphocytes (CD8+ T-cells)
levels; however, the virus is not fully contained by the immune response 63.
This is then accompanied by a chronic or asymptomatic stage that can last 7-10 years
without the patient exhibiting major symptoms of disease progression

17

. Although no

apparent symptoms occur, the virus still replicates and infects new cells causing a
progressive decline in CD4+ T-cells. Decline in CD4+ T-cells may result from cell death
during productive infection in vivo and in vitro 64–66 . Additional, it has been reported that
a decline in CD4+ T-cells may be due to pyroptosis of non-productively infected cells as
demonstrated in vitro 67,68 . After the chronic stage, an increase in the viral load occurs and
the level of CD4+ T-cells drops below 200 cells/mm3 which can lead to the onset of
opportunistic infections and is characteristic of AIDS progression 17.

1.3
1.3.1

Antiretroviral therapy and HIV-1 persistence
Antiretroviral therapy

Antiretroviral therapy was first introduced in the early 1990’s 7. Azidothymidine (AZT)/
Zidovudine mono-therapy, a nucleoside reverse transcriptase inhibitor, was the treatment
of choice to prevent HIV-1 replication and slow disease progression. However, viral
replication occurs rapidly with a high mutation rate of the virus leading to the occurrence
of drug resistant viruses

69

. Consequently, mono-therapy became quickly ineffective as

HIV-1 became resistant to treatment

70,71

. The current treatment option involves

combinations of antiretroviral drugs commonly known as combination antiretroviral
therapy (cART). These combinations of drugs simultaneously target different stages of the
virus life cycle, thus optimizing their effectiveness. There are ~30 approved antiretroviral
drugs categorized as: 1) reverse transcriptase inhibitors that consist of nucleoside or nonnucleoside inhibitors, 2) integrase inhibitors that interfere with the strand transfer activity
of the viral integrase enzyme, 3) protease inhibitors and 4) viral entry inhibitors such as
fusion inhibitors, CCR5 co-receptor antagonists and attachment inhibitors 7.
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cART has been more effective in suppressing viral replication than AZT mono-therapy in
general as the viral load drops below 50 RNA copies/ml while reducing the mortality rate
related to HIV-1/AIDS 7. This led to the hope that cART could potentially eradicate the
virus. Nonetheless, once treatment is discontinued the virus can replicate and produce
infectious particles leading to a rapid rebound in viremia 72. Unfortunately, it is now evident
that cART cannot completely clear the virus from infected individuals. In fact, cART is
mostly effective against replicating virus and preventing new infection of cells

73

. This

further confirms that a replication competent quiescent/latent reservoir of infected cells
exist and can persist despite therapy.

A viral reservoir could be defined as any subset of cells or anatomical sites that harbor a
replication competent form of the virus that persists for a very long time compared to the
pool of actively replicating virus 10. The main cellular reservoir of infected latent cells are
CD4+ memory T cells. This will be further discussed in section 1.3.2. Macrophages are
also potential latent cellular reservoirs of HIV-1 74. More on anatomical reservoirs will be
discussed in section 1.3.3.

1.3.2

HIV-1 viral latency

HIV-1 viral latency is characterized by the low expression levels of viral transcripts or no
expression of viral transcripts where HIV-1 can remain in a long-lived quiescent /latent
state within infected cells

10,11,12

. Latency mainly occurs as a result of a transcriptional

block in HIV-1 expression and is characterized by little to no detectable expression of viral
transcripts as previously described

12,75

. Chromatin modifications and epigenetic

regulations can also lead to HIV-1 latency. These multiple restrictions on HIV-1 expression
are further described below.

HIV-1 latency can occur in two distinct forms: pre-integration or post-integration latency
76

. It is unclear how early latency is established. However, it was shown that early

administration of cART (within 10 days) following the occurrence of symptoms related to
primary infection could not prevent the production of latently infected cells in infected
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individuals 8. Additionally, studies from nonhuman primate suggested that latency can
occur as early as 3 days post infection despite early administration of cART 9.

During pre-integration latency, the virus enters non-dividing cells where reverse
transcription of the viral RNA genome occurs. The viral DNA only gets integrated into the
host cell genome when those non-dividing cells become activated 76. However, since the
pre-integrated complex has a very short half-life of ~1 day, pre-integration latency of the
viral DNA is less likely to be the major contributing factor to the long-term persistence of
HIV-1 infection 77,78,79,80.

Post-integration latency results from the viral DNA integrating into the host genome where
viral gene expression is impeded. Contrary to pre-integration latency, post-integration
latency is highly stable and can persist for a life-time. The best characterized reservoir for
post-integration latency are the resting memory CD4+ T cells. In their resting state, these
cells have a very low metabolic rate and are transcriptionally inactive. Therefore, the
integrated proviral DNA can remain transcriptionally silent and the infection is not targeted
by the immune system or cART 81,82. Upon activation of the infected resting memory cells,
viral production can resume as latency is reversed 83.
HIV-1 latency is thought to be first established when activated CD4+ cells get infected.
Some of the infected and active CD4+ cells that are not killed by the cytopathic effects of
viral replication and the immune system revert back as resting memory cells 82. The result
is a stably integrated latent virus. Additionally, resting memory CD4+ T cells is a stable
latent reservoir for HIV-1 infection. The slow decay rate and long half-life of infected
CD4+ T cells contribute to the stability of the latent reservoir 84,85.

Another contributing factor to the stability of the latent reservoir involves the proliferation
of infected cells

86,87,88

. T cells proliferation or expansion is usually driven by different

stimuli such as antigen and cytokine driven homeostatic proliferation 89. Antigen-induced
proliferation leads to a rapid and transient cell division and amplification of T cell
clones/clonal expansion in response to activation

90,91

. Once antigen exposure is cleared

during antigen-induced proliferation, the majority of T cells die with a small subset that
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revert into resting memory T cells. Homeostatic proliferation leads to clonal expansion
which contributes to the persistence of the viral reservoir 90,91. Homeostatic proliferation is
a process driven by cytokines that is important for the normal maintenance of size and
diversity in the total pool of T cells which enables T cell clones to either maintain their
numbers or expand over time. Recent work further revealed the presence of identical HIV1 integration site positions in the human genome within a large portion of infected CD4+ T
cells

86,87,92,88

. Interestingly, clonally expanded cells showed integration into genes

associated with cell proliferation and growth 87,88 . Expanded cells were also shown to carry
replication-competent latent virus in vivo 93.
Although, HIV-1 latency is first established through infection of activated CD4+ cells
before they revert into memory cells, the molecular mechanisms that maintain latency are
not well understood. It is suggested that HIV-1 latency is a multifactorial process and is
thought to be maintained by: 1) the site and orientation of integration within actively
transcribed genes that can interfere with HIV-1 gene expression 94,95; 2) epigenetic changes
in chromatin structure that prevent the action of transcription factors on the HIV-1
promoter region 82,75; 3) sequestration of cellular factors such as the nuclear factor-kappa
B (NF-ҡB) and nuclear factor of activated T-cells (NFAT) which are essential for HIV-1
transcription and are sequestered in the cytoplasm due to the absence of signaling in resting
CD4+ T cells 75,96. The positive transcription elongation factor b (pTEFb) which associates
with HIV-1 Tat protein to promote elongation of the viral transcripts is also sequestered in
resting CD4+ T cells by cellular regulatory complexes 75,97 ; and 4) microRNA which may
bind to the viral messenger RNA and prevent viral translation 98 .

1.3.3

Sanctuary reservoirs

HIV-1 may persist in anatomical sites or compartments where replication can still occur
due to the limited penetration of cART in these sites. Throughout untreated infection, the
majority of HIV-1 infection occurs in the lymphoid organs such as the gut associated
lymphoid tissue (GALT), the lymph nodes and the spleen

99,100

. In the GALT, a high

frequency of infected cells was observed compared to infection in the circulating blood
despite long-term antiretroviral therapy

101

. This was further associated with cross-
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infection between the GALT compartment and the blood 101. This suggests that the GALT
is a reservoir for HIV-1 infection. Other anatomical sites such as the central nervous system
(CNS), and the genitourinary (GU) tract can also be sites of HIV-1 infection. In the CNS,
HIV-1 primarily infects perivascular macrophages and microglial cells 102,103. In untreated
patients, there is clear evidence that infection in the CNS is compartmentalized.
Specifically, virus isolated from the peripheral blood is distinct from those isolated in the
CNS/ cerebrospinal spinal fluid 104. In the GU, HIV-1 has been found in the seminal fluid
either as unintegrated and integrated virus in latently infected cells 105–107.

1.3.4

Targeting the latent reservoir

HIV-1 latency is multifactorial. Multiple strategies have been proposed to reactivate the
latent reservoir. The most explored strategies are the “Shock and kill” methods. These
methods involve reactivation of the latent virus using latency reversal agents (LRAs) which
allows depletion of the virus through the immune response against infection or therapeutic
means. Some of the earlier LRAs that were investigated involved the use of anti-CD3
antibodies, interferon gamma and interleukin 2 to induce immune activation; however,
these approaches were ineffective as patients experienced global T cell and cytokine
activation

108

. Other methods of reactivation involved the use of histone deacetylase

inhibitors (HDACi) such as suberoylamide hydroxamic acid (SAHA/vorinostat),
romidepsin and panobinostat that counteract chromatin mediated repression 109–111, 112,113–
115

. Phorbol esters such as bryostatin-1 and prostratin that induce HIV-1 transcription via

activation of the host cellular protein kinase C pathway were also used 116–118. Disulfiram
is another LRA that depletes expression of the phosphatase tension homolog (PTEN)
protein which leads to the activation or the phosphorylation of the protein kinase B (Akt)
signaling pathway 119 . Activation of AkT signaling pathway results in HIV-1 reactivation
in an NF-ҡB-dependent manner

119

. Additionally, Toll-like receptor (TLR) agonists have

been used to activate HIV-1 expression in latently infected cells

120

. GS-9620 is a TLR7

agonist that was shown to reactivate HIV-1 expression from cells of infected individuals
on suppressive cART

121

. Other TLR agonists that has been investigated in vivo are the

CPG 7909 and MGN1703 which are both TLR9 agonists

122,123

. Combination of current

LRAs have been administered simultaneously with the hope of enhancing reactivation of
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latently infected cell

124,125

. However, both single use of LRA and combination of LRAs

fail to reactivate the entire pool of latently-infected cells, thus failing to completely purge
the virus. A major factor contributing to this failure is genomic location-driven differences
in HIV-1 expression. These findings suggest that integration location has the potential to
confound these anti-latency treatments and that integration site selection may be a major
contributing factor to latency by influencing proviral gene expression.

1.4
HIV-1 integration process and the viral integrase
structure
HIV-1 must integrate its newly synthesized DNA into the chromosomal DNA for
successful production of new viral progeny. Integration is a permanent event. Thus, the
viral genetic information can be transferred into daughter cells during cell division.
Furthermore, the ability of HIV-1 to integrate into the chromosomal DNA presents a great
challenge for eradication. Once integrated, HIV-1 persists and establishes a latent reservoir
of infected cells that cannot be eliminated with cART. The viral IN enzyme is the key
enzyme that catalyzes the integration reaction.
The integration process is common to other retroviruses and involves 3 major steps: 1) 3’
processing of the reverse transcribed viral DNA, 2) DNA strand transfer or joining of viral
DNA to the target DNA, 3) end repair process 126,127. It should be noted that the IN alone
cannot execute the entire integration process. In fact, IN is part of the pre-integration
complex where the viral DNA associates with other viral and host factors including the IN
itself.

1.4.1

The integration reaction

Figure 1.4 illustrates the 3 main steps of the integration process. Integration into the host
genome is initiated through recognition of the viral DNA by the IN in the cytoplasm. First,
the IN binds to the viral DNA at the viral attachment (att) sites located on both 5’and 3’
ends of the LTR of the viral DNA55,128,129. The IN removes 2 to 3 nucleotides, usually pGT
nucleotides from both 3’ ends of the LTR at the complimentary CA dinucleotide site
130,131,132

. This reaction is known as 3’-processing and occurs in the cytoplasm within the

pre-integration complex. The 3’processing reaction exposes a 3’ hydroxyl (3’-OH) group
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at both ends of the viral DNA55 . As mentioned in section 1.2.4, the viral DNA associated
with IN and other factors forms the pre-integration complex, which is transported into the
nucleus for the strand transfer reaction to take place. The IN mediates a nucleophilic attack
by the 3’-OH groups on phosphodiester bonds of the target DNA. This results in the
cleavage of the target host DNA and the simultaneous 3’end joining of the viral DNA and
the 5’end of the target DNA 55,133,132. The integration sites on the two strands of the target
DNA are separated by 5 nucleotides leaving single-stranded gaps.
Following the strand transfer reaction, two unpaired/overhanging nucleotides at the 5’ ends
of the viral DNA are removed. The single stranded gaps are filled and ligated, possibly by
DNA damage repair enzymes 134,135.

1.4.2

HIV-1 integrase structure

The HIV-1 IN protein is the main player for catalyzing the integration process and is a 288
amino acid protein (32kDa) that is proteolytically cleaved from the Gag-Pol polyprotein
precursor 136. The IN is composed of three major structural and functional domains: the Nterminal domain (NTD), the C-terminal domain (CTD) and a central catalytic core domain
(CCD) (Figure 1.5) 136,55. The structure of the HIV-1 IN domains have been characterized
by X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy 137,138.
The NTD structure (amino acid 1-49) consists of 4 α-helices coordinated by conserved
histidine and cysteine amino acid residues. Specifically, His12, His16, Cys40 and Cys43
(HH CC) binds to a single zinc ion (Zn2+) stabilizing the folded alpha helical structure of
the NTD, which also promotes multimerization of the IN for its activity 139,140.
The CCD (amino acid 50-212) is composed of 6 α-helices and 5 β-sheets

141

and is

conserved among the different retroviruses. Additionally, the CCD consists of a triad of
highly conserved amino acid residues commonly referred to as the D, D, E motif (Asp-64,
Asp-116 and Glu-152).
The DDE residue of the CCD is the catalytic site of the IN enzyme. The DDE residues
coordinates two divalent metal ions (e.g.: Magnesium/Mg2+ or Manganese/Mn2+) that
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Figure 1.4

Figure 1.4: Steps of the integration reaction (adapted from reference 126).
.
The
reverse transcribed viral DNA associates with the integrase (IN) in the pre-integration
complex. During the 3’processing reaction, the IN removes 2-3 nucleotides from both
3’ends of the viral DNA exposing hydroxyl groups. In the strand transfer reaction, the IN
catalyzes 3’ OH group nucleophilic attack on the host DNA. The 3’ end of the viral DNA
and the 5’ end of the host DNA simultaneously link together. The unpaired gaps at the
viral-host DNA junction are filled by host repair enzymes during the gap repair step. The
fully integrated viral DNA is known as the provirus.
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Figure 1.5

Figure 1.5: HIV-1 integrase structure (adapted from reference 127).
HIV-1 integrase (IN) enzyme is a 288 amino acids protein. The IN is composed of three
functional domains: the N-terminal domain (NTD), the catalytic core domain (CCD) and
the C-terminal domain (CTD). The NTD contains a highly conserved HHCC motif (H for
histidine and C for cysteine) that mediates Zn2+ binding. The CCD domain contains a
conserved DDE motif that is part of the catalytic activity of the IN and binds to Mg2+. The
CTD is a less conserved domain and exerts non-specific DNA binding.
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catalyze the 3’processing and DNA strand transfer step of the integration process 130,142,143,.
Specifically, the metal ion binds the D64 and D116 residues of HIV-1 IN

143

. The CCD

has also been shown to be involved in viral DNA recognition and target DNA binding
144,145

. On the other hand, the CTD (amino acids 213-288) is less conserved among the

retrovirus family and is thought to be involved in DNA binding 131,146. Overall, the HIV-1
IN can catalyze both the 3’processing and DNA transfer reaction alone and requires the
use of metal ions for its activity. The role of the IN in the end repair reaction of the
integration process has yet to be shown.
The retroviral integration process can be reproduced in vitro

147,148

. Integration studies

were performed via isolation of the pre-integration complex from infected cells or
purification of the IN

29,149

. The HIV-1 pre-integration complex, was shown to not only

contain the IN, but also included the viral MA, RT, NC and Vpr proteins 56,150. However,
it was also found that a number of host cellular proteins may assist the virus during
integration. In particular, host cellular proteins can have a profound role in integration site
targeting. Currently identified host factors involved in integration are further discussed
below in section 1.4.3.

1.4.3

Host proteins interacting with HIV-1 integrase

A number of approaches have been used to identify candidate host proteins that are binding
partners of HIV-1 IN during integration. These approaches included the yeast-two hybrid
assay for protein-protein interactions 151,152, co-immunoprecipitation153,154, and the in vitro
reconstitution of enzymatic activity of salt-stripped pre-integration complex 155,156.

1.4.3.1

Integrase interactor 1 (IN 1)

Through the application of the yeast-two hybrid assay, the first IN binding protein was
identified

152

. This protein was named integrase interactor 1 (INI1) complex and is the

human homolog of the yeast chromatin remodeling activator SNF5. SNF5 is a transcription
activator and part of the chromatin remodeling SWI/SNF complex

157,158

.

INI1 is

comprised of three highly conserved regions. These regions comprise 2 direct imperfect
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repeats, repeat 1 (Rpt1) and repeat 2 (Rpt2), a C-terminal coiled-coiled domain and a
homology region

159

. The Rpt1 region was shown to be necessary and sufficient for the

HIV-1 IN interaction 159. In vitro studies also demonstrated that INI1 stimulates the strandtransfer activity of HIV-1 IN 152. However, no strong evidence has been found to support
INI1 function in HIV-1 integration in vivo. Other studies found that INI1 can also bind
with different host and viral proteins such as the cMYC 160 and p53 161 host proteins, the
human papilloma virus E1 protein 162 and the Epstein-Barr virus nuclear antigen 2 protein
(EBNA2)163. Other studies have demonstrated a potential role of INI1 during HIV-1
replication as well. Specifically, a fragment containing the minimal IN binding domain of
INI1, located between residues 183-294, induced a substantial decrease in HIV-1
replication/production and release in a transdominant manner
found to be incorporated into HIV-1 virions

164,165

164

. Moreover, INI1 was

and is necessary for the efficient

production of infectious viral particles 164. The Rpt2 region of INI1 was also shown to have
a masked nuclear export domain 166. Currently, it is still unclear whether INI1 is required
for HIV-1 replication or if it is involved during integration in vivo.

1.4.3.2

The barrier-to-autointegration factor (BAF)

The barrier-to-autointegration factor (BAF) is another IN host binding protein that was first
identified in Moloney murine leukemia virus (MoMLV) pre-integration complexes. BAF
is a highly conserved 89 amino acid protein that can bind to double-stranded DNA 167,168.
BAF has also been known to condense DNA structure

169

. BAF was shown to prevent

autointegration of the viral DNA thus averting suicidal integration 155. It was proposed that
BAF prevents autointegration by coating the viral DNA as well as inducing changes in the
viral DNA structure through condensation of the viral DNA

155

. With the use of co-

immunoprecipitation experiment and the use of anti-BAF antibodies, the presence of BAF
was established in HIV-1 as BAF co-immunoprecipitated with the HIV-1 pre-integration
complex

153

. BAF also restored HIV-1 integration activity in experiments where the pre-

integration complexes lost their function following salt-stripped inactivation of the
complex

170

. Additionally, it was shown that BAF associated with the lamina associated

polypeptide LAP-2α, which is involved in chromatin and nuclear structure reorganization
171

. In addition, LAP-2α seems to assist BAF recruitment to the pre-integration complex
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172

. The fact that BAF also interacts with LAP-2α, suggests it potential role in chromatin

reorganization. So far, BAF involvement in stimulating integration has only been observed
in in vitro experiments.

1.4.3.3

High mobility group chromosomal protein A1 (HMGA1)

The high mobility group chromosomal protein A1 (HMGA1, formerly HMGI (Y)) is a
non-histone DNA binding protein that can also interact with other proteins. HMGA1 is
known to control transcription and modulate chromatin structure 156. In the case of HIV1, HMGA1 associated with HIV-1 pre-integration complexes following purification of the
pre-integration complexes from infected cells 156. Moreover, when HMGA1 was added to
salt-stripped pre-integration complexes, recombinant HMGA1 restored the integration
activity in vitro 156. However, HMGA1 seems to show a lower stimulatory effect than BAF
when added to salt-stripped pre-integration complexes to restore integration activity 156,170.
As a DNA binding protein, it was proposed that HMGA1 will interact with the viral DNA,
thus bringing both LTR ends into close proximity and enabling IN binding by unwinding
the ends of the viral DNA

173,174

. However, other studies suggested that HMGA1 is not

required for retroviral integration

175

. Hence, a role for HMGA1 in HIV-1 integration is

still a matter of debate.

1.4.3.4

The lens epithelium-derived growth factor and co-factor
p75 (LEDGF/p75)

The lens epithelium-derived growth factor and co-factor p75 (LEDGF/p75) is a 76 kDa
transcriptional regulatory protein and a member of the hepatoma-derived growth factor
(HDGF) family. LEDGF/p75 is a ubiquitously expressed nuclear protein and mainly
functions in cell growth and protecting cells from stress-induced cell death

176,177

.

LEDGF/p75 accomplishes its protective function by transcriptionally activating antiapoptotic genes and stress related proteins, such as the heat shock proteins 177. LEDGF/p75
is widely accepted as a binding partner of HIV-1 IN. Through co-immunoprecipitation
studies, LEDGF/p75 was found to interact with HIV-1 IN in cells overexpressing IN

154

.

This interaction was further confirmed by another study through yeast two-hybrid
experiments 151. LEDGF/p75 also stimulated the IN strand-transfer activity by binding to
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the IN 178. Most importantly, LEDGF/p75 interaction with IN was mapped to a conserved
~80 amino acids residues at the C-terminus of LEDGF/p75, which has hence been named
the integrase binding domain (IBD) 178–180. The IBD of LEDGF/p75 interacts with the CCD
and NTD of IN. More specifically, the CCD of IN is sufficient for this interaction.
However, additional binding of IBD to the NTD of IN increased the affinity of the
interaction. These interactions were confirmed via protein crystallography

181,182

. The N-

terminus of LEDGF/p75 functions as a chromatin binding region and contains several
domains: 1) the PWWP (Pro-Trp-Trp-Pro) domain that functions as a protein-protein
and/or DNA-binding domain

183

, 2) a nuclear localization signal

184

and 3) a AT-hook

binding domain 185. As such, the N-terminus of LEDGF/p75 binds to chromatin and its Cterminus interacts with IN. Thus, LEDGF/p75 has been shown to function as a tethering
factor that may recruit the IN and other IN binding partners to the chromatin

154,179

.

LEDGF/p75 will be further discussed in section 1.5.3.

1.4.3.5

Other HIV-1 integrase binding proteins

The transportin 3 (TNPO3) protein was identified to be a binding partner of HIV-1 IN via
yeast-two hybrid experiments

186,187

. TNPO3 appeared to be essential in facilitating the

transport of the pre-integration complex into the nucleus

186,187

. However, subsequent

studies reported that the nuclear transport of the pre-integration complex likely functions
through TNPO3 interaction with the viral CA and not with the IN 187,188. Additionally, the
host DNA repair protein Ku70, was shown to directly bind to HIV-1 IN

189,190

. This

interaction was shown to protect the IN from proteosomal degradation by preventing the
IN from ubiquitination

190

. A decrease in HIV-1 integration and replication was also

reported following depletion of the Ku70 protein 190. Ku70 protein was further detected in
HIV-1 virions

190

.

Additionally, cleavage and polyadenylation specificity factor 6

(CPSF6), a 68 kDa protein member of the pre-messenger RNA splicing factors, has been
reported to be involved in the transport of the pre-integration complex from the cytoplasm
to the nucleus through its interaction with the viral CA protein191,192, 193 . Truncation of the
C-terminal domain of CPSF6 impeded the nuclear transport of the pre-integration complex
193,194

.
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1.5
Genomic profile of HIV-1 integration and factors
affecting HIV-1 integration site selection
Understanding HIV-1 integration site selection is of paramount importance especially
when integration site selection can influence proviral gene expression and latency.
Previous studies proposed that specific host DNA sequences could act as a target for HIV1 integration. Thus, the DNA sequence adjacent to the integrated virus was assessed. Using
cell line models, it has been found that HIV-1 preferentially integrates within the
transcription units of active genes

195,196

. These integrations sites are associated with

regions of high G/C content, high gene density, high CpG island density, short introns,
high frequencies of Alu repeats, low frequencies of long interspersed nuclear element
(LINE) repeats, and characteristic epigenetic modifications

195,196,197,198,

. Integration in

active transcription units has been shown during acute infection in different cells types
195,196

. It is important to note that integration site preference differs among the retroviral

family. For example, the gammaretrovirus murine leukemia virus (MLV) is primarily
found integrated at transcription start sites and CpG islands

199,200

. In contrast,

alpharetroviruses, such as the avian sarcoma leukosis virus (ASLV), deltaretroviruses, such
as the human T-lymphotropic virus 1 (HTLV-1), and betaretroviruses, such as the mouse
mammary tumor virus (MMTV), showed no preference for integration within transcription
units 201,202,203,204. Multiple mechanisms/models have been proposed to address integration
site selection. The following three mechanisms/models, none of which are mutually
exclusive, have been proposed to address integration site selection: 1) chromatin
remodeling/accessibility model 2) the cell cycle model and 3) the host factors/proteins
tethering model.

1.5.1

Chromatin remodeling and accessibility model

In the nucleus, eukaryotic DNA is tightly wrapped around histones thus forming chromatin
structures and complexes known as nucleosomes. DNA structure has a propensity to
change during transcription and cell cycle phases, allowing host factors to interact with the
DNA. Therefore, it seemed likely that the virus will integrate in regions that are more
accessible, such as in euchromatin regions. It was then suggested that DNA wrapping into
nucleosomes will alter its accessibility to the pre-integration complex, thus influencing
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integration site selection. In fact, it was found that DNA compaction around nucleosomes
creates hotspots for integration at sites of DNA distortion/bending
integration was also favored on the major grooves of the DNA

206

205–208

. Retroviral

. More specifically,

integration was predicted to occur on the major grooves of DNA facing outward from the
nucleosome

197

. Although the role of DNA wrapping around the nucleosome has been

demonstrated to influence and facilitate integration, chromatin accessibility cannot solely
explain the difference in integration site selection among different retroviruses such as
HIV-1 and MLV.

1.5.2

Cell cycle model

As a lentivirus, HIV-1 is capable of infecting non-dividing as well as dividing cells
209,210,211

. Infection of non-dividing cells can be accomplished through the active nuclear

import of the HIV-1 pre-integration complex 209. Contrary to HIV-1, a lentivirus, gammaretroviruses such as MLV can only infect dividing cells

212

. Thus, MLV requires the

disruption of the nuclear envelope to integrate it viral DNA into the host DNA. As such, it
was proposed that cell division/mitosis could contribute to the differences in integration
site selection seen between HIV-1 and MLV. Since remodeling of the chromatin occurs
during DNA replication, it was further suggested that cell division could lead to an increase
in integration into certain regions as opposed to other sites.
To investigate this hypothesis, studies were performed to assess the integration site
distribution in non-dividing and dividing primary lung fibroblasts cells 195. The integration
profile into other non-dividing cells such as human macrophages was also assessed 213. It
was shown that cell cycle stage did not have a major effect on HIV-1 site distribution 195,213.
As an alternative, it has been proposed that cellular host proteins that bind to the preintegration complexes and the chromosome act as tethering factors for the pre-integration
complexes.

1.5.3

Host factors/proteins tethering model

In this model, it has been proposed that cellular host proteins would interact with the preintegration complex thus targeting the pre-integration complex to specific regions of the
host chromatin. As previously discussed, HIV-1 IN which is also part of the pre-integration
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complex interacts with several host factors such as LEDGF/p75. LEDGF/p75 is the only
known bona fide tethering factor of HIV-1 and other lentiviruses. As a chromatinassociated protein, LEDGF/p75 was shown to be involved in targeting HIV-1 integration
within actively transcribed regions/transcription units214–216.

The role of LEDGF/p75 as a determinant for HIV-1 integration site selection was further
confirmed through knockdown studies. Knockdown of LEDGF/p75 in human cell lines led
to a significant decrease in integration in transcription units and HIV-1 replication 215–217.
However, in the absence of LEDGF/p75, HIV-1 integration was redirected to CpG island
and transcription start sites

217

. This new integration site selection is similar to the

integration site targeting of gamma-retroviruses. This implies that yet other host factors are
involved in integration at the alternative chromosomal locations.

1.6
Non-B DNA structures are new factors influencing
HIV-1 integration site targeting
Primary sequences at around 5-10 bases immediately flanking HIV-1 integration were used
to determine the sequence region surrounding integration site targeted by HIV-1. Through
these in vitro integration site assays, it was found that these short primary sequences had
only minor influences on HIV-1 integration site selection 218–220. One major question that
arose is whether analysis of a larger sequence window would provide more information on
HIV-1 site selection.
We recently characterized the integration site of an HIV-1 based lentivector in the murine
brain by analyzing a larger window surrounding integration sites, up to 40 bases
downstream and upstream of the integration sites. We identified two strong consensus
guanine-quadruplex forming motifs (G4 motifs; also known as tetraplex) flanking the
integration sites

221

. These findings identified a new cis-acting factor affecting

lentiviral/HIV-1 integration site selection. The G4 motif is a member of non-B DNA
forming structures/ motifs. Non-B DNA motifs are DNA structures formed from noncanonical Watson-Crick base pairing with contorted bond angles or unpaired nucleotides
compared with the orthodox B-DNA form 222.
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Further analysis of data from our previous study showed that HIV-1 preferentially
integrates in or near a variety of non-B DNA motifs in different cell lines including murine
brain cells and human cells , such as Jurkat, SupT1, HEK 293, HeLa, and HOS cells as
well as primary human cells such as macrophages, peripheral blood mononuclear cells
(PBMCs)

221

. Taken together, this data demonstrates that pre-integration complexes are

attracted to non-B DNA. Moreover, some of the non-B DNA motifs, such as G4 motifs,
are known to promote recombination and influence genomic stability and cellular processes
such as transcription 223,224. These recent findings are of great interest to our laboratory as
non-B DNA can not only influence HIV-1 integration site selection, but also potentially
influence the establishment and/or maintenance of latency potentially by impeding the
RNA polymerase processivity. These findings also set the foundation for this thesis. Thus,
non-B DNA and HIV-1 integration site selection are the major focus for this dissertation.
More discussion on the canonical B-DNA structure and non-B DNA motifs will be
presented in section 1.6.1 and 1.6.2 respectively.

1.6.1

The canonical B-DNA structure

DNA was first isolated by Friedrich Miescher in 1869 and is the ideal molecule for the
storage of genetic information

225

. More than 80 years following the discovery of DNA,

Rosalind Franklin and Maurice Wilkins demonstrated that DNA forms a repeated helical
structure in 1953 via X-ray analysis 226,227. During that same period following Franklin and
Wilkins’ study, James Watson and Francis Crick elucidated the three dimensional
molecular structure of DNA in 1953

228

. These findings paved the way for a better

understanding of the biological function of DNA.
DNA is a polymer of molecules called nucleotides and is commonly found as a doublestranded helix structure in the cell. Each nucleotide is composed of a nitrogen base linked
to a 5 carbon sugar molecule and a phosphate group that is attached to the sugar molecule
229

. The sugar molecule in DNA is referred to as deoxyribose. There are four different bases

derived from purine and pyrimidine that make up the nucleotides of DNA. The purine bases
are Adenine (A) and Guanine (G). The pyrimidine bases are Thymine (T) and Cytosine
(C). A complementary base interaction exists between the 2 strands of the double helix
DNA where A always pair with T and G pairing with C

229

. These base pairs are further
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stabilized by Watson and Crick hydrogen bonds. Overall, DNA is often found as a doublestranded structure where the nucleotides are linked together by phosphodiester bonds
through the sugars and phosphates forming a chain of alternating sugar-phosphate
backbone. The most commonly described and biological form of DNA is B-DNA.
B-DNA structure consists of two antiparallel polynucleotide chains. The two
polynucleotide chains are held together in the center through hydrogen bonding between
complementary bases. Therefore, the bases occupy the interior of the double helix and the
sugar-phosphate backbones are found on the outside of the helix structure

226,227

. This

molecular organization creates a wide major groove and narrow minor groove in the DNA.
The complementary bases pairings of A-T and G-C as described by Watson and Crick is
also a common feature of B-DNA. With this arrangement of the complementary base
paring in the center, the two sugar-phosphate backbones wind around forming right-handed
double helix structure (Figure 1.6 A).
The structure of the double helix B-DNA can shift to adopt several distinct conformations
based on many factors, including non-canonical base pairing. These non-canonical forms
of DNA are known as non-B DNA structures or motifs.

1.6.2

Non-B DNA structures

In its inactive and non-transcribed state, the DNA structure primarily exists in the form of
the right-handed B-DNA228. However, DNA is dynamic and can assume several alternative
non-B DNA conformations under certain physiological conditions

230,231

. Non-B DNA

structures occur within specific genomic sequences and are in higher energy states. NonB DNA are believed to form at repetitive sequence motifs by the free energy generated
from negative supercoiling of the DNA during replication or transcription, as the DNA
partially unwinds, as well as during protein binding 232,233,234. Overall, non-B DNA occurs
when DNA encounters a high level of torsion or stress. In the human genome, the repeat
DNA sequences that have the potential to fold and form non-B DNA comprise 50% of the
genome. On the other hand, simple sequence repeats account for only about 3% of the total
genomic DNA 235. Currently more than 10 different types of non-B DNA structures have
been identified. This include A-phased repeats, inverted repeats, direct repeats, cruciform
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motifs, slipped motifs, mirror repeats, short tandem repeats, triplex repeats, G4 motifs, and
Z-DNA motifs 222. Examples of non-B DNA structures are presented in Figure 1.6 B.
Non-B DNA appears to play a significant role in several biologically important processes
236

. Specifically, non-B DNA are known to affect DNA replication, transcription,

transcription factor recruitment, initiation repression, stalling of polymerase 223,224,237. They
can also induce genetic instability leading to certain human diseases 234,238,239. Each non-B
DNA motif is described below, followed by a brief description of their potential biological
impact, if known.
- A-phased motifs: A-phased motifs are usually formed by 3 or more tracts of four to nine
adenines or adenines succeeding by a thymidine

240

. They are separated with a central

region containing 11-12 nucleotides.
- Inverted repeats: Inverted repeat sequences are single stranded nucleotide sequences
that are arranged in opposing orientation. Inverted repeats are known to induce genome
instability through excision of the repeat-associated region

241

. They have also been

implicated in gene amplification 242.
- Direct repeats: Direct repeats are DNA sequences that are repeated two or more times
downstream of each other. Direct repeats are shown to flank DNA deletion breakpoints
243,244

.

- Cruciform motifs: Cruciform DNA forms at inverted repeat sequences and requires at
least a 6 nucleotide inverted repeat sequence 232. Cruciform DNA are similar in structure
to the Holliday junction. Cruciform structures are typically located near break point
junctions, replication origins and promoter regions 245,246. They have also been implicated
in regulating DNA replication in diverse organisms including mammalians 246 .
- Slipped motifs: Slipped motifs, are formed by direct repeat DNA sequences that present
a certain symmetry 234. These transient structures typically form during DNA replication
and transcription. As the DNA strand unwinds, these direct repeat sequences on the single
stranded DNA have the opportunity to fold back due to mispairing of the repeat units on
the same strand 234.

31

Figure 1.6

Figure 1.6: Canonical B-DNA structure and non-B DNA structures (adapted from
reference 236).
(A) Structure of canonical right handed double helix B-DNA. (B) Examples of non-B DNA
structures. Triplex DNA is formed from (R.Y) mirror repeat sequence. Z-DNA is formed
from alternating pyrimidine-purine sequences (YR_YR) n. Guanine-quadruplexes are
formed from oligo (G)n tracts and cruciform structures are formed from inverted sequences.
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The presence of these motifs has been associated with neurodegenerative and
neuromuscular diseases 247,248.
- Mirror repeats: Mirror repeats are DNA sequences that are separated with a center of
symmetry

249

. Mirror repeats are known to cause replication fork stalling due to their

propensity of folding into triplex 250.
- Short tandem repeats: Short tandem repeats (STR) or microsatellites are short simple
repeats of DNA sequences. Each repeat unit is about 1-6 bases long and are A-rich in the
human genome 251,252. STR can have a length of up to 100 nucleotides. STRs are present
in 3% of the human genome and occur every 2000 bp in the human genome. They are
mostly found in non-coding regions

252

. Some short tandem repeats are thought to act as

transcription regulator and can affect certain genes expression. They may also be involved
in recombination and could be associated with certain neurodegenerative diseases 252.
- Triplex repeats: Triplex DNA can form due to the presence of long stretches of purinepyrimidine (R_Y) mirror repeat sequences

234

. There are two different types of triplex

DNA: intermolecular and intramolecular. Intermolecular triplexes are triplexes that are
formed between a duplex DNA and a triplex forming oligonucleotide (TFO) via Hoogsteen
pairing 253. Intramolecular triplexes are formed from a duplex DNA with homopurine and
homopyrimidine at sites of DNA supercoiling

253

. An example of intramolecular triplex

DNA are H-DNAs. Triplex sequences are predicted to be present in promoter and
intergenic region near introns

254

. Triplex DNA has been implicated in regulating gene

expression and genetic recombination 255,256.
- Guanine-quadruplex (G4) motifs: G4 motifs form secondary structures formed by
guanine rich nucleic acids. G4 can assemble in G4-tetrads (G-G-G-G). Within a
quadruplex, two to three tetrads stack together to form a compact, four-stranded DNA. The
tetrad structure is stabilized by cations (Na+, K+) and hydrogen bonds in the center of the
plane

257

. G4s have been found to be located in promoter region of oncogenes

258

and

telomeres of chromosomes 224,257. They can induce genomic instability in mammalians and
bacteria 259.

33

- Z-DNA motifs: Z-DNA is a left-handed DNA helix structure. Z-DNA is formed based
on alternating pyrimidine-purine sequences ((YR_YR) n)235. Compared to the canonical B
DNA that have a major and a minor groove, Z-DNA only has a deep groove

235

. These

motifs are more stable due to the energy release from negative supercoiling and they are
usually present at transcription start sites, promoter region of genes and the 5’ends of genes
260,261

. Z-DNA can induce genomic instability. In fact, Z-DNA has been shown to cause

double-strand breaks in mammals and bacteria, resulting in large scale deletions and
chromosomal rearrangements 259.

1.7

Research overview and rationale

cART helps suppress HIV-1 replication in infected individuals, but it fails to eradicate virus
from latently-infected reservoirs, such as memory CD4+ T cells and macrophages. These
latent proviruses are long-lived and undetectable by the immune system. Notably,
proliferation of CD4+ T cells through clonal expansion can further expand the latent
reservoir. The potential for even a single virus to reinitiate infection despite successful
antiviral therapy implies that it is necessary to eliminate all replication competent latent
proviruses in order to eradicate HIV-1 from an infected individual. HIV-1 integration
within active transcriptional units might promote viral gene expression and maximize viral
production during the short lifespan of infected cells. In contrast, HIV-1 integration in
low/inactive regions of genomes, such as satellite DNA, gene deserts and centromeric
heterochromatin, has also been previously described 262–264. It is possible that these regions
might be involved in the establishment of latently-infected cells and HIV-1 persistence.
Mechanisms underlying integration sites choice are not fully understood.
Furthermore, most of the studies available examine only the integration profile of HIV-1
subtype B, which is mostly prevalent in the Americas, Europe, Australian, Japan and
Thailand. However, multiple subtypes and recombinants dominate other regions of the
world, with 95% of HIV-1 infections occurring in developing countries. Subtype C
contributes to most infection worldwide. Therefore, performing a comparative study of
integration site profiles involving different subtypes will help determine if the site
preferences seen with HIV-1 subtype B are common to all HIV-1 subtypes, and how this
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may contribute to disease persistence. Additionally, the integration site selection of HIV1 in compartmentalized sanctuary sites from infected individuals have not been defined.
Integration sites studies will also provide more insights on the integration site profile seen
in different latent reservoirs.

Given our previous findings that non-B DNA influences HIV-1 integration site selection
and that certain non-B DNA motifs such as the G4 motifs can regulate gene expression, I
proposed to further characterize the role of non-B DNA motifs in HIV-1 integration site
selection and their contribution to HIV-1 persistence. Furthermore, I proposed to further
investigate the integration site profile in evolutionary diverse retroviruses (e.g. HIV-1, SIV,
MLV, and MMTV) with respect to non-B DNA.

1.8

Hypothesis

I hypothesized that host genomic non-B DNA motifs are favored in retroviral integration
target site selection and that integration near non-B DNA contributes to HIV-1 persistence
in latently infected cells. To address my hypothesis, I first characterized the integration site
profile in productively and latently infected cells. I further assessed the integration profile
among different HIV-1 subtypes (A, B, C and D) and other retroviruses in order to
determine if any variation exists between their integration site preferences. Lastly, I
delineated the integration site profile of different HIV-1 latent tissue reservoirs such as the
brain/CNS and the gastrointestinal tract (GIT).

1.9
1.9.1

Thesis Chapters Overview
Specific host DNA structures are genomic beacons for
integrated, quiescent/latent HIV-1 in patients receiving
treatment

In chapter 2, I present analyses of the distribution of HIV-1 integration sites in productively
infected cells, latently infected cells as well as clonally expanded cells, and non-clonally
expanded cells. We have demonstrated a distinct integration profile in latently infected
cells and clonally infected cells in different genomic regions. We have shown that HIV-1
favored integration in or near specific non-B DNA motifs in productively infected cells,
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latently infected and clonally expanded cells and that these genomic features may attract
HIV-1 for integration. Analysis of integration site placement in LEDGF/p75 and CPSF6
depleted cells showed that integration in or near specific non-B DNA was influenced by
LEDGF/p75 and CPSF6. Additionally, we showed a strong bias toward integration into
guanine-quadruplex (G4) structures that are generally associated with transcriptional
silencing.

1.9.2

Non-B DNA structures are universally targeted by
evolutionarily diverse retroviruses for integration

In chapter 3, I extended our analysis by assessing the integration distribution in
evolutionary diverse retroviruses and in different HIV-1 subtypes. Throughout our analysis
we were able to demonstrate that non-B DNA motifs are also targeted by other retroviruses
and exhibit distinct integration profiles. Additionally, we showed via next generation
sequencing of subtypes A, C and D that they exhibit an integration site profile that differs
from subtype B, the most studied subtype. Importantly, integration site analysis from
patient datasets correlated with integration into non-B DNA motifs know to suppress gene
expression (e.g. G4 motifs and Z-DNA). Lastly, antiretroviral therapy altered HIV-1
integration site targeting, with enriched integration near G4 motifs observed in patients
receiving antiretroviral therapy for subtypes A and C.

1.9.3

The quiescent/latent HIV-1 integration site landscape from
different anatomical tissues reveals unique differences

In chapter 4, I have characterized the integration site profile in various anatomical sites
(brain, PBLs/PBMCs and parts of the GIT) that harbor latent viruses during HIV-1
infection. We found that HIV-1 integration was enriched in genes in PBLs/PBMCs and the
GIT. Integration into genes was strongly disfavored in the brain. Most importantly,
integration was strongly enriched in or near non-B DNA motifs, which can play substantial
role in regulating adjacent genes expression.
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Chapter 2

2

Specific host DNA structures are genomic beacons for
integrated, quiescent/latent HIV-1 in patients receiving
treatment

Elimination of the latent reservoir is essential for curing HIV-1 infection. Integration sites
of latent proviruses play a critical role in the clonal expansion, persistence and reactivation
of HIV-1 expression. To better understand the local genomic environment surrounding
integrated proviruses and its contribution to latency, we characterized integration site
datasets from productively and latently infected cells. We showed that integration sites are
enriched in and/or near non-B DNA motifs/structures, and that lens epithelium-derived
growth factor (LEDGF)/p75 and cleavage and polyadenylation specificity factor 6
(CPSF6) influence this integration site targeting. Non-B DNA integration site profiles from
productively and latently infected cells, including clonally and non-clonally expanded
cells, are distinct. Importantly, we demonstrated a strong correlation between integration
sites, guanine-quadruplex (G4) motifs and reactivation of latent proviruses with latency
reversal agents. Our findings implicate non-B DNA as a key factor in HIV-1 integration
site targeting and the establishment and maintenance of latency.

2.1

Introduction

An essential step in the life cycle of HIV-1 is the integration of its viral genome into the
human genome. This event is permanent and leads to life-long persistence of the virus
within its host. Combination antiretroviral therapy (cART) suppresses productive HIV-1
replication in infected individuals, thereby reducing circulating virus to undetectable levels
1

. Despite this, resting memory CD4+ T-cells harbor integrated virus that persists in a

transcriptionally silent state referred to as latency

2,3

. HIV-1 remains latent indefinitely

until reactivated by means that are not fully understood, but include cessation of
antiretroviral therapy, development of antiretroviral resistance or clinically-directed ‘shock
and kill’ therapy 4. Latency presents a major obstacle in curing an individual of HIV-1
infection. This is in part due to the slow decay rate of the latent reservoir after cART
initiation, which has an estimated half-life of 44 months and an eradication timeline of >70
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years in a patient 5,6. Although the size of the latent pool is under much debate, modeling
studies have suggested that expansion and contraction of latently infected cells can
generate low-level persistent viremia and intermittent viral blips that can replenish the
latent reservoir 7–9. Therefore, elimination of the latent reservoir is essential for eradication
of the virus from the body.
Multiple mechanisms have been attributed to establishing and maintaining proviruses in a
latent state and are likely not mutually exclusive. For example, the site and orientation of
integration, availability of cellular transcription factors and viral proteins, epigenetic
regulation of the HIV-1 promoter, and microRNA regulation of chromatin remodeling and
targeting of messenger RNAs have been shown to contribute to HIV-1 latency 10,11. ‘Shock
and kill’ strategies have been proposed to flush out latent HIV-1 reservoirs to induce
depletion of the virus for a cure. The main objective of these strategies is to facilitate the
reactivation of HIV-1 expression from latent reservoirs, which are then destroyed through
either natural means (e.g. immune response and viral cytopathogenicity) or artificial means
(e.g. drugs and antibodies)

12

. Many latency reversing agents have been used for

reactivation including physiological stimuli, chemical compounds (phorbol esters), histone
deacetylase (HDAC) inhibitors, p-TEFb activators, and antibodies (e.g. anti-CD3);
however, these agents fail to reactivate the entire pool of latently infected cells

13–16

.

Although somewhat controversial, several reports suggest that this failure is due to
genomic location-driven differences in HIV-1 expression 14,16–21. Specific integration sites
are also associated with clonal expansion of latently infected cells

22

. Clonally expanded

cells have been shown to produce infectious HIV-1 in vivo; however, this may not be the
case in all infected individuals 23,24. A better understanding of the molecular mechanisms
contributing to the establishment and maintenance of latency will help current eradication
strategies.
Much of the early retroviral integration site analyses focused on the most frequent
integration events in an attempt to better understand the genomic environment surrounding
sites that result in productive infection. Comparatively, there are fewer integration site
analyses with respect to latent infection. This is likely attributed to the rarity of latent
integration events and the small number of cells comprising the latent reservoir. Several
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groups have proposed that the features affecting latency are highly local and heterogeneous
16,19,20,25

. HIV-1 LTR promoter activity was also shown to be sensitive to the local

chromatin environment in such a way that it is not directly controlled by DNA methylation
or histone acetylation in cell lines 18,26. Importantly, the insertion site affects the response
to latency reversal agents (LRAs), where different LRAs can activate different subsets of
proviruses in the whole latent population 16,19. These different subsets were distinguishable
in terms of chromatin functional states and only represented <5% of cells carrying a latent
provirus 16. Furthermore, host cellular proteins such as LEDGF/p75 and CPSF6 have been
shown to promote integration into actively transcribed genes residing in gene-dense
regions, thereby reducing integration into other genomic regions conducive to latency such
as heterochromatin 27–36.
We previously identified non-B DNA as a novel factor that influences HIV-1 integration
site targeting in acute infection 37. Non-B DNA motifs are abundant in the human genome
and form secondary structures using non-canonical Watson-Crick base pairing. At least 10
non-B DNA conformations exist including G4 motifs, A-phased repeats, inverted repeats,
direct repeats, cruciform motifs, slipped motifs, mirror repeats, short-tandem repeats,
triplex repeats and Z-DNA motifs 38. Several non-B DNA motifs preferentially act as the
recipient of genetic information, stimulating homologous recombination >20-fold in
human cells

39

. Non-B DNA structures (e.g. G4, Z-DNA, cruciform and triplex motifs)

have also been shown to potently silence expression of adjacent genes 40–50.
In this study, we analyzed HIV-1 integration site profiles of productively and latently
infected cells and identified a strong correlation between non-B DNA motifs and latent
proviral integration sites. In particular, we showed that G4 motifs significantly influence
integration site targeting and proviral reactivation potential by certain LRAs. Moreover,
we showed that LEDGF/p75 and CPSF6 impact integration targeting of non-B DNA
motifs.
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2.2
2.2.1

Materials and methods
Cell lines

Human embryonic kidney 293T (HEK 293T) cells were obtained from the American Type
Culture Collection. HEK 293T cells were maintained in standard Dulbecco’s Modified
Eagles Medium (DMEM) (Wisent, cat#:319-005-CL) or phenol red free DMEM (Wisent,
cat#:319-051-CL) at 37°C with 5% CO2 in a humidified incubator. All media were
supplemented with 10% heat-inactivated fetal bovine serum ([FBS], [Wisent, cat#:080450, lot#: 115690]), 100U/ml penicillin and 100µg/ml streptomycin.

2.2.2

Virus production

Pseudotyped HIV-1/VSV-G was generated by co-transfecting HEK 293T cells (plated at
3.5x106 cells in 10cm dish) with plasmids p156RRLsinPPTCMVGFPWPRE (encoding the
HIV vector segment), pCMVdeltaR9 (the packaging construct), and pMD.G (encoding the
VSV-G envelope) as previously described 51. The three plasmids were kindly provided by
Dr. F. Bushman (University of Pennsylvania, USA). Co-transfection was performed using
5µg of each plasmid with LipoD293 (FroggaBio, cat#: SL1006680.1) following the
manufacturer’s instructions. 24 hours post co-transfection, the cells and culture medium
were harvested and centrifuged at 1500 rpm (239x g) for 5 min at room temperature. The
supernatants were collected and stored at -80°C and were used to infect cells as described
in section 2.2.3.

2.2.3

Drug treatment and genomic DNA extraction

BRACO19 hydrochloride (BRACO19) was purchased from Sigma Aldrich (cat.
#SML0560-5MG). TMPyP4 was purchased from Calbiochem-EMD Millipore (cat.
#613560-25MG). 0.5x106 HEK 293T cells were plated in 6 well plates for 24 hours. The
cells were then left untreated (control) or treated for 24 hours with either BRACO19 (0, 1,
3, and 32 µM) or TMPyP4 (0, 0.5, 1 and 8 µM). BRACO19 and TMPyP4 concentrations
were established from previously used concentrations 52,53,54. Cells were then infected for
5 hours with pseudotyped HIV-1/VSV-G (800µl of DMEM, 200µl of HIV-1/VSV-G virus)
in the presence of 1µl of 10µg/ml polybrene [(Sigma, cat#: H9268-5g]). Medium was
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changed 5 hours post-infection and the cells were treated anew with either BRACO19 or
TMPyP4 for 24 hours. The genomic DNA was then extracted from the cells as per
manufacturer’s instructions using the DNeasy Blood and Tissue Kit (Qiagen, cat#: 69504)
and processed for integration site profile analyses (see section 2.2.5).

2.2.4

MTT assay

Cell metabolic activity was measured using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5Diphenyltetrazolium Bromide) kit (Thermo Fisher Scientific, cat#: M6494). HEK 293T
cells were plated (0.2x106) in 24 well plates with phenol red free DMEM for 24 hours.
Cells were treated with either BRACO19 (0, 1, 3, and 32 µM) or TMPyP4 (0, 0.5, 1 and 8
µM). 24 hours post-treatment, the medium was changed and the cells were incubated for 5
hours at 37°C without treatment. This step was performed to reproduce conditions during
infection as described in section 2.2.3. The cells were later treated with BRACO19 and
TMPyP4 for an additional 24 hours. Following the second treatment, MTT solution was
added at a final concentration of 0.5mg/ml. The samples were incubated for 1 hour at 37°C.
100µl of DMSO (EMD, cat#: MX1456-6) was added to solubilized the purple formazan
crystals for 10 min on a shaker. Absorbance of the plates were read at 540 nm using the
Epoch microplate spectrophotometer (BioTek) plate reader and the Gen5.2.06 analysis
software. To determine the percent (%) cell viability, the average values of the blank wells
(medium + MTT solution) were subtracted from each sample read (BRACO19, TMPyP4
treated and untreated samples). Untreated value was used as positive control from which
the % cell viability was determined.

2.2.5

HIV-1 integration library

Genomic DNA extracted from infected treated and untreated HEK 293T cells (see section
2.2.3) was processed for integration site analysis and sequenced using the Illumina MiSeq
platform. First, 1µg of extracted genomic DNA was restriction enzyme digested with MseI
overnight at 37°C. Digested DNA was column purified with the Gel/PCR DNA Fragments
Kit (Geneaid, cat#: DF100) according to manufacturer’s instructions. Next, compatible
double-stranded linkers to the MseI sites were prepared as follows: MseI Linker (+)
5’GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC 3’and MseI Linker (-): 5’
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[Phos]-TAGTCCCTTAAGCG GAG-[AmC7-Q] 3’ were mixed (20µl MseI Linker (+) [40
µM] and 20 µl MseI Linker (-) [40 µM]). The linker mixture was denatured for 5 min at
90°C and cooled 1°C every 3 min until the temperature reached 20°C using the T100TM
Thermal Cycler (Bio-Rad). The prepared linkers are now referred to as the “adapter mix”.
Purified DNA was linker ligated with the adapter mix at 21°C for about 14 hours with
13.5µl of MseI digested samples, 3.5µl of adapter mix, 1µl of T4 DNA Ligase (400U/µl,
[NEB, cat#: M0202S), and 2 µl of 10x ligase buffer. Subsequently, 20µl of the ligated
sample was digested at 37°C for 4 hours with 2µl of DpnI (20U/µl), 2µl of NarI (5U/µl),
5µl of 10x buffer and water to a total volume of 50µl. Following digestion, the samples
were column purified. The junctions between the integrated HIV-1 LTR sequence and
adjacent genomic sequence were amplified in two separate rounds of PCR amplification.
The HIV-1 NL4-3 LTR sequence were used to design primers that amplify through the
HIV-1 LTR. The RuparLTR (Forward) 5’-TGCTTCAAGTAGTGTGTGC-3’ primer that
anneals to the HIV-1 LTRs and the Linker1 (Reverse) 5’-GTAATACGACTCACTATAG
GGC-3’primer specific to the MseI linker sequences were used for the first round of PCR
amplification. Each PCR reaction mixture consisted of 15.5µl sterile water, 5µl of
NarI/DnpI digested sample, 2.5µl of 10x Advantage 2 PCR Buffer, 0.5 µl of 15µM of
Linker1 primer , 0.5 µl of 15µM RuparLTR primer, 0.5µl of 10mM dNTPs and 0.5 µl of
50X Advantage 2 PCR polymerase mix (Takara Bio Inc., cat#:639201). PCR was run on
T100TM Thermal Cycler (Bio-Rad) under the following cycling conditions: 1 min at 94°C,
5 cycles of 2 sec at 94°C, 1 min at 72°C with an additional 20 cycles of 2 sec at 94°C, 1
min at 67°C and a final extension cycle for 1 min at 72°C and a 4°C hold. The second
round of nested PCR amplification was performed using sample from the first round of
PCR amplification. The PCR reaction mixture and cycling condition were as described for
the first round of PRC amplification. The following primer set was used for nested PCR:
Rupar-LTR2nested

(Forward)

5’-CTCTGGTAACTAGAGATCCCTCAGACC-3’,

Linker2nested (Reverse) 5’-AGGGCTCCGCTTAAGGGAC-3’ and Next, Illumina
adapter overhang nucleotide sequences were added to the HIV-1 LTR sequence and the
MseI linker sequence. Illutag-Forward 5’-GTCTCGTGGGCTCGG AGATGTGTATAA
GAGACAGCTCTGGTAACTAGAGATCCCTCAGACC-3’ and Illutag-Reverse 5’TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGGGCTCCGCTTAAGGGA
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C-3’. Underlined section of the two Illutag primers represent the overhang section. Illumina
adapters were utilized in a PCR reaction mixture contained 15.5µl sterile water, 5µl of
nested PCR samples, 2.5µl of Advantage 2 PCR Buffer (10x), 0.5 µl of Forward adapter
(10µM), 0.5 µl of Reverse adapter (10µM), 0.5µl of dNTPs (10mM) and 0.5 µl of 50X
Advantage 2 PCR polymerase mix. PCR was run on T100TM Thermal Cycler (Bio-Rad).
Cycling conditions were as described for the first round of PRC amplification.
The PCR product were purified with AmPure XP beads (Beckman Coulter, cat#: A63881)
and the DNA samples were processed using Nextera XT Index Kit (Illumina). The Nextera
XT Indexes technology utilizes a single tagmentation reaction that fragments and tags
input DNA with unique adapter and index (barcodes) sequences on both ends of the DNA
as previously described

37

. The DNA samples were purified using AmPure XP beads

following addition of the barcodes. The barcoded samples were quantified using the Quantit PicoGreen dsDNA Assay Kit (Invitrogen, cat#: P7589). The absorbance of the plates
were read (excitation 480nm for 10 sec and emission 540 nm for 10 sec) with the Cytation5
Imaging Reader (BioTek) and the Gen5 3.02.1 analysis software. Sample concentration
was determined using a standard concentration curve. The barcoded samples were
sequenced through Illumina MiSeq using 2 × 150 bp chemistry at the London Regional
Genomics Centre at the Robarts Research Institute (Western University, Canada).

2.2.6

Computational analysis

Fastq sequencing reads were quality trimmed and unique integration sites identified using
our in-house bioinformatics pipeline

37

, which is called the Barr Lab Integration Site

Identification Pipeline (BLISIP version 2.9). BLISIP version 2.9 includes the following
updates: bedtools (v2.25.0) which is used to compute distances between integration sites
and genomic features, bioawk (awk version 20110810) a programming language for
biological data manipulation, bowtie2 (version 2.3.4.1) is used for aligning sequence reads
to the human genome, and restrSiteUtils (v1.2.9) is used to generate in silico matched
random control integration sites based on restriction enzyme used or DNA shearing
methods. HIV-1 LTR-containing Fastq sequences were identified and filtered by allowing
up to a maximum of five mismatches with the reference NL4-3 LTR sequence and if the
LTR sequence had no match with any region of the human genome (GRCh37/hg19).
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Integration site profile heatmaps were generated using our in-house python program
BHmap (BHmap version 1.0). Sites that could not be unambiguously mapped to a single
region in the genome were excluded from the study. Mapping of integration sites to non-B
DNA motifs was performed using the Non-B DB for the human genome (GRCh37/hg19)
55, 56

as previously described 37. Lamina associated domains (LADs) were retrieved from

http://dx.doi.org/10.1038/ nature06947 57.

2.2.7

Datasets analysis

All integration site datasets used in this study were independently analyzed using BLISIP
version 2.9. The Cohn dataset was obtained from the National Center for Biotechnology
Information Sequence Read Archive (NCBI SRA) using the accession number SRP045822
as described

24

. The Battivelli dataset was obtained from the “Integration Sites – Source

Data” as described

16

. The Maldarelli/Wu dataset was obtained from the supplemental

material as described 22. The Achuthan dataset was obtained from the NCBI SRA using the
accession number SRP132583 as described 34. All genomic sites in each dataset that hosted
two or more sites (i.e. identical sites) were collapsed into one unique site for the analysis.

2.2.8

Statistical analysis

The Fisher’s exact test was used for all comparisons of integration site distributions in
Figures 2.1B, 2.1C, 2.1D, 2.2B, 2.2C, 2.2D, 2.3, 2.4B, 2.4C, 2.4D and 2.5D. A single factor
ANOVA test was used to confirm significant changes within the experiment for Figure
2.5C. For all Figures, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

2.2.9

Data and software availability

The sequences reported in this paper have been deposited in the National Center for
Biotechnology Information Sequence Read Archive (NCBI SRA) (SRP164286:
SRR7975450-SRR7975468).
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2.3
2.3.1

Results
HIV-1 integration sites in quiescent/latently infected cells are
enriched in and near non-B DNA motifs

To determine if there is a correlation between HIV-1 integration sites and non-B DNA
motifs during latent infection, we analyzed the integration site profile of a previously
published HIV-1 integration dataset by Cohn and colleagues

24

. This dataset contained

integration sites that were obtained from primary CD4+ T cells from 13 HIV-1 infected
individuals, categorized as untreated viremic (3,210-71,857 viral RNA copies/ml before
therapy), untreated controller (<50-880 viral RNA copies/ml before therapy) and treated
(<40 viral RNA copies/ml after therapy) groups (Figure 2.1A, Table 2.1 and
Supplemental Table 2.1). To generate integration site profiles, we used an in-house
bioinformatics pipeline designed to maximize the number of unique integration sites as
similarly described 37,58. The integration site profiles were compared with matched random
control (MRC) datasets generated in silico.
In agreement with the work of Cohn et al. (2015)

24

and others 59, integration sites in all

three patient groups were enriched in genes and short interspersed nuclear elements
(SINEs) (e.g. Alu elements) and disfavored in long interspersed nuclear elements (LINEs)
(Figure 2.1B). Integration sites in the treated group were also enriched within 500 base
pairs (bp) of satellite DNA, which is abundant in heterochromatin (P < 0.0001). This is in
contrast with the untreated viremic and controller groups where integration sites were
significantly depleted in and near satellite DNA (P < 0.001). In contrast with the untreated
controller and treated groups, integration sites in the viremic group were enriched in CpG
islands and disfavored in endogenous retroviral elements (ERVs) (P < 0.0001).
Although all groups exhibited enriched integration in genes, the untreated controller group
also exhibited enrichment near genes (1-499 bp) compared to the untreated viremic and
treated groups (P < 0.0001). Together, these data confirm previous findings by Cohn et al.
(2015) and others and show that integration sites in treated patients are enriched near
heterochromatin.
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Table 2.1: List of integration site datasets used in chapter 2.
Dataset

Group

# of unique

Cell Type

Reference

Primary CD4+

Cohn et al.

T-cells

(2015)

integration
sites
Cohn

Untreated Viremic

Untreated

26,342

26,034

Controllers
Treated

Primary CD4+
T-cells

101,881

Primary CD4+
T-cells

Maldarelli/Wu

Clonal

Non-clonal

216

1507

Primary CD4+

Maldarelli

T-cells

/Wu et al.

Primary CD4+

(2014)

T-cells
Battivelli

Productively

950

Infected (PIC)
Reactivated

153

Latently Infected

Primary CD4+

Battivelli

T-cells

et al.

Primary CD4+
T-cells

(RLIC)
Non-Reactivated

669

Latently Infected

Primary CD4+
T-cells

(NRLIC)
Achuthan

Wild type (WT)

277

293T cells

(2018)

73

LEDGF/p75

2949

293T cells

depletion (BID)

Achuthan
et al.
(2018)

CPSF6 depletion

4431

293T cells

Untreated

2017

293T cells

BRACO19 (1 µM)

797

293T cells

BRACO19 (3 µM)

1073

293T cells

BRACO19 (32 µM)

759

293T cells

TMPyP4 (0.5 µM)

1223

293T cells

TMPyP4 (1 µM)

1286

293T cells

TMPyP4 (8 µM)

1302

293T cells

(A77V)
This study

This study
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Figure 2.1: HIV-1 integration sites in quiescent/latently infected cells are enriched in
and near non-B DNA motifs. (A) Table showing the range of viral load and CD4+ T cells
counts from the untreated viremic, untreated controller and treated groups. (B) Heatmap
depicting the fold enrichment or depletion of integration sites in common genomic features
compared to the matched random control (MRC). (C) Bar graphs representing the
proportion of unique HIV-1 integration sites in various non-B DNA motifs. Asterisks
denote significant differences from MRC. (D) Heatmap depicting the fold enrichment or
depletion of integration sites in non-B DNA motifs compared to the MRC. Within each
heatmap, numbers represent the fold-change in the ratio of integration sites compared to
MRC sites. Darker shades represent higher fold-changes. Fisher’s exact test was used for
all comparisons. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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To assess the correlation between the same integration sites from the Cohn dataset and
integration in or near non-B DNA motifs, we quantified integration sites within 500 bp of
several different non-B DNA motifs from each of the treatment groups. As shown in
Figure 2.1C, integration sites from each group were significantly enriched within 500 bp
of all non-B DNA motifs examined, except for A-phased motifs.
To examine integration site placement more local to the non-B DNA motifs, we quantified
integration sites directly within the non-B DNA motif itself or in distance bins of 50 bp up
to 500 bp away from the feature. As shown in Figure 2.1D, the integration site profile
differed among the different treatment groups, especially between the viremic and
controller/treated groups. Notably, integration sites were enriched directly in G4 motifs, ZDNA motifs and short tandem repeats of the controller and treated groups (compared to
the MRC), whereas integration sites in the viremic group were enriched 150-399 bp away
from these features. Integration directly in cruciform motifs, Z-DNA motifs and slipped
motifs was strongly disfavored in the viremic group compared to both controller and treated
groups. Furthermore, integration sites in the controller and treated groups were notably
enriched 150-399 bp away from triplex motifs compared to the viremic group. Together,
these data show that HIV-1 favors integration in and/or near non-B DNA motifs in infected
individuals, and that a distinct integration site bias for specific non-B DNA motifs exists
based on treatment status.

2.3.2

Integration near G4 motifs is associated with proviral
reactivation in quiescent/latently infected cells

Recently, it was shown by Battivelli and colleagues that HIV-1 integration sites were
distinguishable with respect to chromatin functional states and that these locations
correlated with latency reactivation

16

. This integration site dataset was generated by

infecting primary CD4+ T cells with a novel dual-fluorescence HIV-1 reporter virus
(HIVGKO) designed for the accurate quantification and purification of a large number of
latently infected cells as previously described

16

. Briefly, the HIVGKO reporter is a dual-

color reporter that carries the HIV-1 promoter in the 5’LTR driving a codon-switch eGFP
(csGFP) expression and the cellular elongation factor one alpha (EF1α) promoter that
drives expression of the monomeric kusabira-orange2 (mKO2) fluorescent protein. The
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HIVGKO reporter virus allows for quantification and discrimination of productively infected
cells (csGFP positive, mKO2 positive), latently infected cells (csGFP negative, mKO2
positive) and uninfected cells (csGFP negative, mKO2 negative) (Figure 2.2A). Sorted
latently infected cells were then subjected to reactivation with the αCD3/CD28 LRA

16

.

Overall, the Battivelli study involved three populations of HIV-1infected cells. The first
population contained productively-infected cells (PIC), whereas the second population
contained latently infected cells that could be reactivated with the αCD3/CD28 LRA which
are the reactivated latently-infected cells (RLIC) and the third population contained cells
that could not be reactivated with the αCD3/CD28 LRA which are the non-reactivated
latently-infected cells (NRLIC) (Figure 2.2A). We first assessed the integration site
selection with respect to the most common genomic features. In agreement with the
Battivelli study, integration sites in each of the PIC, RLIC and NRLIC populations were
enriched in genes (compared to the MRC), with the majority of sites located in genes (82%,
70% and 59% respectively) (Table 2.1, Figure 2.2 B and Supplemental Table 2.2).
We also observed that the frequency of integration directly in DNaseI hypersensitivity sites
in the NRLIC population was not significantly different from the frequency expected for
random placement. Also in agreement, integration sites in the NRLIC population were
enriched in regions of heterochromatin (compared to the MRC), such as those containing
satellite DNA (P < 0.0001). This is in contrast with the PIC population where integration
sites were depleted in satellite DNA. The proportion of integration sites in heterochromatic
lamin associated domains (LADs) were also enriched in the RLIC and NRLIC samples
(25% and 29%) compared to the PIC samples (14%) (Supplemental Table 2.2). Together,
these data show that our bioinformatic analyses agree with the findings of the Battivelli
study and further supports an integration site bias towards regions of heterochromatin in
latently infected cells.
We then analyzed the Battivelli integration site dataset to determine if proviral reactivation
in latently infected cells correlated with a distinct non-B DNA integration site profile.
Integration sites in the PIC populations were enriched within 500 bp of direct repeats,
inverted repeats, mirror repeats, short tandem repeats, and slipped motifs (Figure 2.2 C

79

Figure 2.2: Integration near G4 motifs is associated with proviral reactivation in
quiescent/latently infected cells. (A) Schematic depicting isolation of the productivelyinfected cells (PIC), the reactivated latently-infected cells (RLIC) and the non-reactivated
latently-infected cells (NRLIC) population from the Battivelli dataset. The αCD3/CD28
was used for reactivation of latently infected cells in the Battivelli dataset (B) Heatmap
depicting the fold enrichment or depletion of integration sites in the most common genomic
features compared to the matched random control (MRC). The ‘RLIC+NRLIC’ population
was compared to the PIC population. (C) Bar graphs showing the proportion of unique
HIV-1 integration sites in non-B DNA motifs. Asterisks denote significant differences
from the MRC (D) Heatmap depicting the fold enrichment or depletion of integration sites
in non-B DNA motifs compared to the MRC. The ‘RLIC+NRLIC’ population was
compared to the PIC population. Within each heatmap, numbers represent the fold-change
in the ratio of integration sites compared to MRC sites. Darker shades within each hetmap
represent higher fold-changes. Within each heatmap, infinite number (inf) indicates that 1
or more integrations were observed when 0 integrations were expected by chance. Not a
number (nan) indicates that 0 integrations were observed and 0 were expected by chance.
Fisher’s exact test was used for all comparisons. * P < 0.05, ** P < 0.01, *** P < 0.001,
**** P < 0.0001.
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and Supplemental Table 2.2). Integration sites in the RLIC populations were enriched
within 500 bp of all non-B DNA motifs except for A-phased and G4 motifs. Integration
sites in the NRLIC populations were enriched within 500 bp of all non-B DNA motifs
except for A-phased motifs, mirror repeats, triplex motifs and Z-DNA motifs. To examine
integration site placement more local to the non-B DNA motifs, we quantified integration
sites directly in the non-B DNA motif itself or in bins of 50 bp up to 500 bp away from the
feature. Distinct differences in the integration site profiles were observed for each of the
different populations (Figure 2.2D and Supplemental Table 2.2). Notable differences
were identified for cruciform, G4, slipped, triplex and Z-DNA motifs, where integration
was highly enriched in and/or near these features in the RLIC and NRLIC populations
compared to the MRC. In contrast with the RLIC and NRLIC populations, integration sites
in the PIC population were enriched in, but not near, cruciform motifs.
After comparing the frequency of integration sites in the RLIC+NRLIC populations with
the PIC population, we observed strong enrichment of integration sites in and/or near most
non-B DNA motifs, indicating that the latently infected populations were more enriched in
these motifs compared to the productively infected population (Figure 2.2D and
Supplemental Table 2.2). Distinct differences in integration site profiles were also
observed between the RLIC and NRLIC populations, particularly with respect to G4,
slipped and Z-DNA motifs. Integration sites in the NRLIC population were enriched in
these motifs. In striking contrast, integration sites in the RLIC population were depleted in
these features, but highly enriched within 1-49 bp of these features. Integration sites in the
RLIC population were also highly enriched within a region 250-450 bp away from inverted
repeats, short tandem repeats, triplex motifs and Z-DNA motifs compared to the NRLIC
population. Together, these data show that integration sites in latently infected cells are
more enriched in and/or near non-B DNA motifs compared to productively infected cells.
Furthermore, reactivation of latent proviral expression correlates with integration site
placement adjacent to, but not within, G4, slipped and Z-DNA motifs.
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2.3.3

CSPF6 and LEDGF/p75 promote integration into specific
non-B DNA

The interaction of CPSF6 with HIV-1 capsid protein licenses HIV-1 pre-integration
complexes to bypass peripheral heterochromatin in the nucleus and penetrate the nuclear
interior to locate gene-dense euchromatin for integration. Lens epithelium-derived growth
factor (LEDGF/p75) is a host factor that tethers the HIV-1 pre-integration complex to
euchromatin where it promotes integration into transcriptionally active genes
63,34

28,29,31–33,60–

. To determine if CPSF6 and LEDGF/p75 influence the targeting of non-B DNA motifs

for integration, we analyzed the recently published integration site dataset by Achuthan
and colleagues (2018) who studied the impact of CPSF6 and LEDGF/p75 on integration
site targeting

34

. In that study, CPSF6 function was depleted by using the HIV-1 capsid

mutant A77V, which impairs CPSF6 binding efficiency without severely decreasing
infectivity. LEDGF/p75 function was depleted by treating cells at the time of infection
with the allosteric integrase inhibitor BI-D, which competes with integrase-LEDGF/p75
binding and inhibits HIV-1 integration.
Consistent with the findings of Achuthan and colleagues, independent CPSF6 depletion
and LEDGF/p75 depletion resulted in decreased integration within genes and increased
integration into heterochromatin (e.g. LADs and satellite DNA) compared to the wild type
control (Table 2.1 and Supplemental Table 2.3). CPSF6 and LEDGF/p75 depletion also
correlated with a strong reduction in integration sites within CpG islands compared to the
control. With respect to non-B DNA, CPSF6 and LEDGF/p75 depletion resulted in
substantial reductions in the percentage of integration sites falling within 500 bp of G4
motifs, mirror repeats, short tandem repeats and Z-DNA compared to the wild type control
(Figure 4, Table 2.1 and Supplemental Table 2.3). Although not achieving statistical
significance, increases in the percentage of integration sites falling near A-phased motifs,
slipped motifs and triplex motifs were observed with CPSF6 and LEDGF/p75 depletion.
Analysis of the distribution of integration sites around the non-B DNA motifs revealed that
integration was generally disfavored at several 50 bp distance intervals from most non-B
DNA features compared to the control cells.
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Figure 2.3: CPSF6 and LEDGF/p75 promote integration into specific non-B DNA.
Graphs show the percentage of total unique HIV-1 integration sites located in or within
500 bp of various non-B DNA motifs (distributed in 50 bp bins) from wild type (control),
CPSF6 depleted or LEDGF/p75 depleted cells. Inset numbers show the percentage of total
unique integration sites falling within 500 bp of the non-B DNA motif. Heatmaps show the
fold enrichment (blue) or depletion (red) of integration sites at each distance interval from
the non-B DNA motif compared to the matched random control (MRC). Fisher’s exact test
was used for all comparisons. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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However, integration sites were highly enriched 1-150 bp away from G4 motifs and 300500 bp away from slipped motifs in cells depleted of CPSF6 compared to the control cells.
Together, these data confirm that CPSF6 and LEDGF/p75 promote integration in genes
and gene-dense euchromatin and show that they also promote integration near the non-B
DNA features G4 motifs, mirror repeats, short tandem repeats and Z-DNA.

2.3.4

Clonally-expanded quiescent/latently infected cells exhibit a
distinct non-B DNA integration site profile

Previous studies have demonstrated that a large fraction of HIV-1 infected cells in patients
can arise from expansion of a single cellular clone (Figure 2.4A) 22–24. Maldarelli and Wu
and colleagues identified specific HIV-1 integration sites linked to this clonal expansion,
particularly integration into genes involved in cellular growth, development and
persistence

22

. We analyzed the Maldarelli/Wu dataset to determine if there are distinct

non-B DNA integration site profiles for clonal and non-clonal populations of latently
infected cells. Our analysis showed that the integration site profiles between these two
populations of cells were highly similar with respect to several common genomic features
with integration strongly favoring genes and DNaseI hypersensitivity sites (Figure 2.4B,
Table 2.1 and Supplemental Table 2.4) when compared to the matched random control
(MRC).
With respect to non-B DNA motifs, our analysis revealed that both clonal and non-clonal
populations favored integration near many non-B DNA motifs, with the non-clonal
population exhibiting significantly more enrichment near non-B DNA motifs compared to
the MRC (Figure 2.4C and Supplemental Table 2.4). Integration sites in the clonal
population were enriched near cruciform motifs, inverted repeats, mirror repeats and short
tandem repeats, although significance was only achieved for inverted repeats. Integration
sites in the non-clonal population were significantly enriched near direct repeats, inverted
repeats, mirror repeats, short tandem repeats and slipped motifs. Analysis of integration
site placement more local to the motifs revealed distinct integration site profiles between
the clonal and non-clonal populations (Figure 2.4D and Supplemental Table 2. 4).
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Figure 2.4: Clonally-expanded quiescent/latently infected cells exhibit a distinct nonB DNA integration site profile. (A) Schematic depicting the isolation of clonallyexpanded and non-clonally-expanded populations in the Maldarelli/Wu study. (B)
Heatmap depicting the fold enrichment or depletion of integration sites in common
genomic features compared to the matched random control (MRC). (C) Proportion of
unique HIV-1 integration sites in various non-B DNA motifs. Asterisks denote significant
difference from MRC (D) Heatmap depicting the fold enrichment or depletion of
integration sites in non-B DNA motifs of the clonal or non-clonal populations compared to
the MRC or to each other. Darker shades represent higher fold-changes. Within each
heatmap, infinite number (inf) indicates that 1 or more integrations were observed when 0
integrations were expected by chance. Not a number (nan) indicates that 0 integrations
were observed and 0 were expected by chance. Fisher’s exact test was used for all
comparisons. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
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Integration was highly disfavored in all non-B DNA motifs except inverted repeats in the
clonal population compared to the non-clonal population. However, integration sites in the
clonal population were enriched in regions spanning 1-149 bp and/or 350-450 bp away
from most motifs. Notably, integration sites in the non-clonal population were significantly
enriched directly in G4 motifs. Together, these data identify distinct non-B DNA
integration site profiles for clonally- and non-clonally-expanded cells.

2.3.5

G4 structure influences integration site targeting in the
genome

The only non-B DNA motif where integration sites were consistently and significantly
enriched in or near the motif in the latently infected populations from each of the Cohn,
Battivelli and Maldarelli/Wu datasets was G4 motifs. To determine the influence of G4
structures on integration site targeting in the human genome during HIV-1 infection, we
utilized G4 structure-stabilizing and -destabilizing ligands. G4 structures consist of four
guanine bases which are stabilized by hydrogen bonds forming a G-tetrad in a planar
arrangement (Figure 2.5A) 64. BRACO19 is a 3,6,9-trisubstituted acridine derivative that
interacts with and stabilizes G4 structures (Figure 2.5B) 52,65–69. We asked if stabilization
of G4 structures increased the frequency of integration in and/or near G4 motifs. HEK
293T cells treated with increasing concentrations of BRACO19 for 24 hours were infected
with HIV-1 pseudotyped with the vesicular stomatitis virus G envelope glycoprotein
(HIV/VSV-G). Twenty-four hours after infection, the integration site profile was
determined for each drug concentration and compared to the infected untreated control
cells. No significant reduction in cell viability was detected after treatment with BRACO19
using the MTT assay (Figure 2.5C). Treatment of cells with increasing concentrations of
BRACO19 resulted in a substantial increase in the proportion of integration sites located
250-499 nucleotides away from G4 motifs (Figure 2.5D, Table 2.1 and Supplemental
Table 2.5). In contrast, integration was strongly disfavored in and adjacent to (1-149 bp)
G4 motifs. Interestingly, integration sites were highly enriched 150- 199 bp from G4 motifs
at low concentrations of BRACO19 and became less enriched at higher concentrations.
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Figure 2.5: G4 structure influences integration site targeting in the genome. (A)
Depiction of the nucleoside arrangement of a guanine-quartet and the G4 structure. (B)
Structure of the TMPyP4 and BRACO19 compounds. (C) HEK 293T cells were treated
with increasing concentrations of BRACO19 or TMPyP4 for 48 hours and the percent cell
viability was determined using the MTT assay. Data are represented as mean ± SEM of at
least 3 independent experiments. (D) Heatmap depicting the fold enrichment or depletion
of integration sites in G4 motifs compared to untreated infected cells. Significance was
determined by Fisher’s exact test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
(E) Data from D shown spatially with respect to the G4 structure and flanking
nucleosomes.
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Figure 2.5

Figure 2.5: G4 structure influences integration site targeting in the genome.
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The cationic porphyrin 5,10,15,20-tetra (N-methyl-4-pyridyl) porphin (TMPyP4) interacts
with and destabilizes non-telomeric G4 structures while, paradoxically, stabilizing G4
structures located in telomeric DNA (Figure 2.5B)

53,54,69–72

. We asked if destabilization

of non-telomeric G4 structures reduced integration in and/or near G4 motifs. HEK 293T
control cells or cells treated with increasing concentrations of TMPyP4 were infected with
HIV/VSV-G. No significant reduction in cell viability was detected after treatment with
TMPyP4 using the MTT assay (Figure 2.5C).
Twenty-four hours after infection, the integration site profile was determined for each drug
concentration and compared to the integration site profile from untreated cells. Treatment
of cells with increasing concentrations of TMPyP4 resulted in a substantial reduction in
the proportion of integration sites directly in, and 250-499 nucleotides away from, G4
motifs (Figure 2.5D, Table 2.1 and Supplemental Table 2.5). Unexpectedly, low
concentrations of TMPyP4 caused an enrichment in integration sites located 250-499 bp
away from G4 motifs. Intriguingly, when integration site placement between the
BRACO19 and TMPyP4 datasets were compared, the largest changes in integration site
enrichment occurred between ~300-450 bp away from the G4 motif, consistent with a
region of DNA located approximately three nucleosomes away (Figure 2.5E). Together,
these data show that modulating G4 structure stability in the host genome significantly
influences HIV-1 integration site targeting in and near G4 motifs.

2.3.6

Integration in or near G4 motifs favors G4 structures with
long loops

Putative G4 structures are identified using the motif GxNy1GxNy2GxNy3Gx

73

. The motif

consists of four guanine tracts with three intervening loops (Figure 2.6 A). In this
expression, x represents the number of guanine nucleotides, Ny1-Ny3 represent the 3
intervening loops and can be categorized as short-loop G4 structures (1-7 nucleotides) or
long-loop G4 structures (>7 nucleotides) based on the number of nucleotides (N) in the
loop. Loop-length has been shown to play an important role in G4 structure stability and
protein-binding specificity

74,75

. We asked if HIV-1 integration sites in latently infected

cells are biased towards G4 motifs with short or long loops and if loop-length is associated
with clonal expansion or reactivation of latently infected cells.
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Figure 2.6: Integration in or near G4 motifs favors G4 structures with long-loops. (A)
Schematic depicting a G4 motif (left) and G4 structure (right) consisting of four adjacent
runs of two or more guanines, with three loop regions of nucleotide subsequences (L1, L2
and L3) connecting the G-runs. Loops containing <7 nucleotides are considered short-loop
(SL) G4s (solid red line), whereas >7 are considered long-loop (LL) G4s (dashed red line).
(B) G4 motifs hosting integration sites or located in or within 500 bp upstream or
downstream of an integration site were identified from the Cohn, Maldarelli/Wu and
Bativelli datasets. The percentage of G4 motifs in each dataset classified as short-loops or
long-loops were compared in the bar graphs. The average loop lengths for each of the three
loops were calculated and are shown below the bar graphs.
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Figure 2.6

Figure 2.6: Integration in or near G4 motifs favors G4 structures with long-loops.
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G4 motif sequences were extracted from the Cohn, Battivelli and Maldarelli/Wu datasets
that hosted integration sites directly in the motif or within 500 bp upstream or downstream
from the motif. The average loop-lengths were calculated and compared for each of the
three loops from each dataset. The average loop-lengths were 10-11 nucleotides for loop
1, 17-18 nucleotides for loop 2 and 9 nucleotides for loop 3 (Figure 2.6B). No substantial
differences in the average loop-lengths were observed between any of the datasets.
Notably, the majority of G4 motifs in each dataset contained a longer loop 2 than loop 1 or
loop 3. Together, these data indicate that HIV-1 integration is biased towards long-loop G4
structures and that loop-length does not correlate with clonal expansion or reactivation
potential of latently infected cells.

2.4

Discussion

The data presented herein show that non-B DNA motifs are novel features that influence
HIV-1 integration site targeting in HIV-1-infected cells. Importantly, we identified non-B
DNA as a genomic feature that correlates with the establishment and maintenance of HIV1 latency. We showed that the locations of integration sites that predominate in latently
infected cells are enriched in or near non-B DNA motifs, some of which are well-known
to inhibit gene expression such as G4, cruciform, Z-DNA and triplex structures

40–50

.

Latently infected cells, including those that underwent clonal expansion, also demonstrated
a distinct non-B DNA integration site profile compared to non-clonally-expanded cells,
with a bias for integration near specific types of non-B DNA, especially long-loop G4
motifs. Treating cells with G4 ligands that stabilize or destabilize G4 structures altered
integration site preference for G4 motifs. Remarkably, integration adjacent to G4 motifs
correlated with the ability of latent proviruses to be reactivated by LRAs.
The ability of HIV-1 to target non-B DNA structures for integration has several important
implications for productive and latent infection. Numerous non-B DNA structures are
associated with active genes in vivo and contribute to a dynamic interplay between DNA
structure, chromatin organization and transcriptional activities

76

. In fact, non-B DNA

structures are recognized by non-B DNA-specific transcription factors, leading to
transcriptional activation

77–80

. Conversely, the unusual non-B DNA structure can block
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binding of B-DNA-specific transcription factors, resulting in constitutive repression of
adjacent genes

81–84

. The non-B DNA sequence itself might alter the intrinsic sequence

preference of nucleosomes, thereby affecting nucleosome occupancy

76,85

. Similarly, the

non-B DNA structure might sterically exclude nucleosomes, thereby affecting nucleosome
positioning 76,86. Indeed, G4 motifs form in nucleosome-free regions in the genome 87. As
such, this ability to locally and dynamically organize flanking nucleosomes may contribute
to transcriptional regulation of adjacent genes and integrated proviruses. Intriguingly, our
analyses revealed a notable enrichment of integration sites at intervals of ~150 bp away
from non-B DNA motifs, which may be a result of this non-B DNA-induced repositioning
of nucleosomes, which are comprised of ~147 bp of DNA wrapped around a histone
octamer core 88.
Our data analyses are consistent with recent studies showing that integration does occur at
low levels in heterochromatin, and that the frequency of integration in heterochromatin is
much higher in latently infected cells compared to productively infected cells

16,18

. The

factors that attract integration into heterochromatin are not fully understood. G4 structures,
which are known to repress transcription, are highly localized to heterochromatin 82. These
structures are typically not found within DNA wrapped around a histone octamer, which
could create a partially open state in heterochromatin for integration directly into or
adjacent to these structures
motif-containing DNA

87,89

90–99

. Notably, HIV integrase is known to bind directly to G4

. Alternatively, it is also possible that G4-structure-binding

proteins serve as tethers for the pre-integration complex as observed for LEDGF/p75.
It has been previously suggested that an optimally tuned bias for integrating into
transcriptionally active (euchromatin) versus inactive (heterochromatin) regions of the
genome may help establish a diverse latent viral reservoir

100,101,102

. CPSF6 and

LEDGF/p75 are two host proteins that promote integration into euchromatin. Specifically,
CPSF6 traffics the pre-integration complex away from peripheral heterochromatin in the
nucleus towards gene-dense regions in the interior, whereas LEDGF/p75 promotes
integration within transcriptionally active genes. We showed that both LEDGF/p75 and
CPSF6 expression resulted in increased integration near non-B DNA motifs, especially
those known to influence gene expression (e.g. G4 and Z-DNA motifs). Although the
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mechanism by which LEDGF/p75 and CPSF6 increase integration near non-B DNA is
unknown, it is possible that LEDGF/p75 and CPSF6 recognize certain non-B DNA
structures (directly or indirectly via non-B DNA-binding proteins) and promote
interactions between the pre-integration complex and the genomic DNA leading to
integration.
Research efforts have attempted to purge the latent HIV-1 reservoir via LRAs to force
expression of proviruses so that the infected cells can be cleared via the immune system or
cytopathic effects 4,103. Unfortunately, currently available agents have proven ineffective,
reactivating only a small proportion (<5%) of cells carrying a latent provirus 16,18,19,104–106.
We showed that the ability of latent proviruses to become reactivated by αCD3/CD28 LRA
correlated with integration sites situated adjacent to, but not in, G4, Z-DNA and slipped
motifs. This is in contrast with non-reactivatable latent proviruses whose integration sites
are enriched directly in the motifs and, in the case of G4, more distal (250-400 bp) to the
motif. Given that G4 and Z-DNA have been shown to interfere with the assembly of
transcription pre-initiation complexes and/or polymerase elongation, it is possible that
expression of proviruses integrated near these non-B DNA motifs can be silenced by these
structures, thereby contributing to latency 41,48,49. In addition, the proximity of integration
sites to these motifs may play an important role in the ability of LRAs to reactivate proviral
expression.
The importance of clonal expansion of latently infected cells is not fully understood, but it
is thought to be important for persistence of HIV-infected cells. The mechanism driving
this clonal expansion is also unknown; however, there is a correlation of increased
integration events in genes involved in the growth and development of cells

107

.

Additionally, it is also thought that antigen stimulation and homeostatic cytokine-driven
proliferation may contribute to clonal expansion thus helping maintain the latent reservoir
108,109

. In the present study, we observed enrichment of integration sites adjacent to several

non-B DNA motifs, particularly G4 motifs, in clonally expanded cells. Interestingly, G4
structures and several other non-B DNA structures, are highly enriched in genes involved
in growth and development or their promoters

76,110–114

. Abnormal expression of genes

involved in developmental regulation can be detrimental (e.g. oncogenic transformation)
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and are repressed most of the time. This is likely attributed to their localization in
facultative heterochromatin. Non-B DNA structures located in the promoter of these genes
may be incompatible with the assembly of the transcription complex, explaining the
paucity of RNA polymerase II at these sites. It is possible that G4 and other non-B DNA
motifs, play an important role in attracting integration into regions of the genome critical
for prolonged persistence of expanded clones. This is biologically important given that a
single integration event can generate a latently infected cell that could undergo clonal
expansion, thereby seeding and maintaining the latent reservoir. While the current data
identifies non-B DNA as a target for integration in clonally expanded cells, it is unclear
how many clonal cells harbor replication competent virus. Therefore, it is possible that the
number of integration sites could be inflated from cells containing defective virus.
Previous searches to identify a consensus sequence for integration site targeting have only
revealed an apparent weak palindromic sequence at the site of insertion of several
retroviruses. Recent work by Kirk and colleagues challenged this notion by showing that
the palindromic consensus sequence arises in the population average as a consequence of
non-palindromic motifs existing in equal proportions on the plus and minus strand of the
target sequence 115. Our study not only supports the notion that there is not likely a single
palindromic consensus sequence at the integration site but shows that the integration sites
are heterogeneous in nature, many of which fall into or near different types of non-B DNA
motifs. In fact, we inspected each of the non-palindromic sequences identified by Kirk and
colleagues in subpopulations of target integration sites from HTLV-1, HIV-1, MLV, ASLV
and PFV (IV) and found that they all represent different non-B DNA sequences that are all
predicted to form slipped-strand DNA structures. This shows that despite having distinct
nucleotide consensus sequences (palindromic or non-palindromic), the nature of the
sequence is such that it is predicted to form non-B DNA slipped-strand structures. Our
findings using G4-stabilizing and -destabilizing ligands further highlights the likelihood
that it may not be the primary DNA sequence itself that plays an important role in attracting
the HIV-1 pre-integration complex, but rather the secondary structure formed by the nonB DNA motif itself. Additionally, we found that treating cells with G4 stabilizing and
destabilizing ligands altered integration site preference for G4 motifs. It is important to
note that in our study, infection was performed with pseudotyped HIV-1/VSV-G leading
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to a single round of infection. As a result, it is possible that variation in integration site
preference might occurs when compared to the integration site preference during
prolonged, long-termed infection in vivo. We also showed that structural variations in these
non-B DNA structures may also be important for attracting integration since HIV-1
demonstrated a strong bias for integration in or near long-loop G4 structures instead of
short-loop G4 structures. Short-loop G4 motifs ((TTAGGG)n) are highly enriched in the
telomeres of chromosomes, for which no bias for HIV-1 integration has been observed.
In conclusion, our findings that HIV-1 integration sites in latently infected cells are
enriched in and/or near non-B DNA motifs indicates that non-B DNA structures,
particularly G4 structures, contribute to the establishment and maintenance of HIV-1
latency. Manipulation of these structures could be a novel approach for improving ‘shock
and kill’ and/or ‘block and lock’ therapies aimed at HIV-1 cure.
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Chapter 3

3

Non-B DNA structures are universally targeted by
evolutionarily diverse retroviruses for integration

In an effort to characterize retroviral integration sites, in this study we present an analysis
of the integration sites of different HIV-1 subtypes and other retroviruses. Using several
published integration site datasets, and samples from HIV-1 infected population from a
Uganda and Zimbabwe cohort, we showed differences in integration sites between
evolutionary diverse retroviruses, HIV-1 infected in vitro and patient datasets and between
HIV-1 subtypes A, B, C and D. Integration was highly enriched in and/or near non-B DNA
motifs for all subtypes and in other retroviruses. Particularly, integration targeting in and
near G4 motifs were strongly enriched in patients compared to in vitro datasets and this
was also associated with integration of latent proviruses during antiretroviral therapy.
Moreover, we showed that antiretroviral therapy significantly alters the integration site
profile of different HIV-1 subtypes.

3.1

Introduction

Two defining features of the replication cycle of retroviruses such as human
immunodeficiency virus type 1 (HIV-1) is reverse transcription of the single-stranded viral
RNA genome into double-stranded complementary DNA (cDNA) and the subsequent
integration of the cDNA into the chromosomal host DNA 1. Reverse transcription is
performed by the reverse transcriptase (RT) enzyme. The integration reaction is mediated
by the viral integrase (IN) protein that interacts with the viral cDNA and other host and
viral proteins forming the pre-integration complex

2,3

. Integration is an essential step in

the retrovirus life cycle. In the case of HIV-1 infection, stable insertion of the viral cDNA
into the host genome results in a persistent life-long infection. Although combination
antiretroviral therapy (cART) substantially suppresses HIV-1 viral replication in infected
individuals and improves their quality of life, HIV-1 still remains an incurable infection 4.
The emergence of drug resistant viruses during prolonged cART treatment

5,6

, increase in

the genetic diversity of the virus 7, high rate of viral replication and residual viremia that
can replenish the reservoir to maintain an on-going replication

8–10

all contribute to the
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difficulty in curing HIV-1 infection. The existence of a small pool of transcriptionally
quiescent/latent cells that are reactivated when treatment is interrupted is a major obstacle
for an effective cure 11,12. Latently infected cells are established early during infection. The
site of integration in the genome has been proposed to contribute to a transcriptional block
in HIV-1 gene expression13,14. Integration site profiles from evolutionarily diverse
retroviruses have also been performed and each exhibits a unique integration site profile
with some common genomic features15–23 . In one of the first pioneering studies, integration
of murine leukemia virus (MLV) was shown to have a strong preference for gene
promoters and was linked to the activation of oncogenes

24,25

. Therefore, a better

understanding of the genomic environment surrounding integration sites in evolutionarily
diverse retroviruses will provide more insight into pathogenesis, as well as the mechanisms
that retroviruses use to integrate into their target host genomes.
Retroviral integration site selection is not a random process. For instance, early studies
investigating HIV-1 integration site preferences showed that HIV-1 favors active
transcriptional units and genes for insertion

26,27

. These gene rich regions are usually

associated with several chromosomal features, including a high GC and CpG islands
content, high Alu repeat elements, low long interspersed nuclear elements (LINEs) and
DNaseI hypersensitive sites. Moreover, a number of studies also reported HIV-1
integration to occur within transcriptionally silent regions of the genome such as gene
deserts, centromeric heterochromatin, satellite DNA, introns and alphoid repeats
28,29,30,31,32

. Comparable to HIV-1, other lentiviruses like the simian immunodeficiency

virus (SIV) and feline immunodeficiency virus (FIV) have been shown to also integrate
within transcription units of actively transcribed genes, while disfavoring integration into
transcription start sites

18,17,19

. In contrast to these complex retroviruses, MLV integrates

near transcription start sites, in gene promoters and near CpG islands 15. Similar to MLV,
integration of the foamy virus (FV) showed preference for integration in the vicinity of
CpG islands and transcription start sites 20. While certain retroviruses showed preference
for integration into specific sites, other retroviruses such as avian sarcoma leukosis virus
(ASLV) and human T-lymphotrophic virus 1 (HTLV-1) showed the most random
distributions, with weaker preferences for transcription units, transcription start sites, genes
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and CpG islands

23,22,19

. Mouse mammary tumor virus (MMTV) also exhibited no

significant preference for transcription start sites or CpG islands 16.
Several factors have been implicated in influencing integration site selection. During HIV1 infection, it has been reported that the condensed or relaxed structure of the chromatin
influences access of the pre-integration complex to the target DNA. For example, wrapping
of the DNA around the nucleosome creates sites of DNA distortion that facilitate
integration especially within the major groove of the DNA 33,34,35,36. Host proteins are also
critical in influencing integration site selection. One of the best described host tethering
protein is lens epithelium derived growth factor and co-factor p75 (LEDGF/p75)

37,38

.

LEDGF/p75 interacts with HIV-1 integrase (IN) and targets the pre-integration complex to
transcriptionally active genes 39,40. Another host factor called cleavage and polyadenylation
specificity factor 6 (CPSF6) interacts with the viral capsid protein and allows HIV-1 to
bypass integration into nuclear peripheral heterochromatin, thereby promoting integration
into

gene-rich

regions

of

the

nucleus

41

.

Furthermore,

the

host

cellular

protein bromodomain and extraterminal domain (BET) proteins (Brd2, -3, -4) has been
demonstrated to interact with MLV IN enzyme promoting integration near transcription
start sites 42. We previously assessed the primary sequence flanking HIV-1 integration in
the genome and discovered that HIV-1 integration sites were highly enriched near
specialized genomic features called non-B DNA motifs

30

. Non-B DNA motifs are

secondary structures in our genome formed by specific nucleotide sequences that exhibit
non-canonical DNA base pairing. At least 10 non-B DNA conformations have been
identified, including guanine-quadruplex (G4)/tetraplex, A-phased repeats, inverted
repeats, direct repeats, cruciform, slipped motifs, mirror repeats, short-tandem repeats,
triplex repeats and Z-DNA 43,44. Moreover, we found integration to be enriched in or near
certain non-B DNA motifs that are known to regulate gene expression45,46,47,48. Notably,
integration sites in latently infected cells that were enriched near G4 and Z-DNA motifs
could not be reactivated by the αCD3/CD28 latency reversing agent (see chapter 2). These
findings suggest that targeting of non-B DNA motifs for integration can influence the
establishment and maintenance of HIV-1 latency. So far, the integration site selection
preferences of other retroviruses belonging to different genera has not been analyzed with
respect to non-B DNA motifs.
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Thus far, HIV-1 integration site analyses have only been conducted on subtype B
infections. It is unknown if the integration site profiles of HIV-1 non-subtype B viruses
differ from subtype B virus. Based on phylogenetic analyses of full-length genomic
sequences, HIV-1 isolates are classified into four distinct groups: group M, N, O and P

49

.

HIV-1 M group accounts for the majority of the global pandemic and is subdivided into
nine subtypes or clades (A, B, C, D, F, G, H, J and K)

49

. Subtype A and F are further

divided into sub-subtypes. Additionally, several circulating recombinant forms (CRFs) and
unique recombinant forms (URFs) have been identified. CRF and URF are the result of a
recombination event between two different subtypes 50. HIV-1 geographical prevalence is
extremely diverse. Most group M subtypes are present in Sub-Saharan Africa. Subtype C
which represents more than 50% of the infection worldwide is prevalent in Africa and Asia
51

. Subtype B infection is common in the Americas, Europe, Australia, and part of South

Asia, Northern Africa and the Middle East. Subtypes A, D, F, G, H, J and K occur mostly
in Sub-Saharan Africa. Infection with CRFs and URFs occurs in most geographical areas
around the world. Infections with groups N, O and P have been found in confined regions
of West-Central Africa

52

.

In this study, we present a comprehensive and comparative analysis of the integration site
profiles of diverse retroviruses and from individuals infected with different HIV-1
subtypes. Our analyses revealed significant differences in the integration site profiles
among different retroviruses and different HIV-1 subtypes, particularly with respect to
non-B DNA motifs. Moreover, antiretroviral treatment strongly altered the integration site
profile in HIV-1 infected individuals. Since non-B DNA structures are known to
significantly influence gene expression, the targeting of non-B DNA structures by HIV-1
may play an important role in the establishment and maintenance of latency and/or disease
progression among different HIV-1 subtypes.

3.2
3.2.1

Materials and methods
Ethics statement and participants samples

Details pertaining to the Uganda study population have been reported previously

53–56

.

Briefly, women who became HIV-1 infected while participating in the Hormonal
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Contraception and Risk of HIV Acquisition Study in Uganda were enrolled upon primary
infection with HIV-1 into a subsequent study, the Hormonal Contraception and HIV-1
Genital Shedding and Disease Progression among Women with Primary HIV Infection
(GS) Study. Ethical approval was obtained from the Institutional Review boards (IRBs)
from the Joint Clinical Research Centre and UNST in Uganda, from University of
Zimbabwe, from the University Hospitals of Cleveland, and recently, from Western
University. All adult subjects provided written informed consent and no child participants
were included in the study. Protocol numbers and documentation of these
approvals/renewals are available upon request. Blood and cervical samples were collected
every month for the first six months, then every three months for the first two years, and
then every six months up to 9.5 years. Women who had CD4 lymphocyte counts of 200
cells/ml and/or who developed severe symptoms of HIV infection (WHO clinical stage IV
or advanced stage III disease) were offered combination antiretroviral therapy (cART) and
trimethoprim-sulfamethoxazole

(for

prophylaxis

against

bacterial

infections

and Pneumocystis jeroveci pneumonia).

3.2.2

DNA isolation and HIV-1 integration library

Total genomic DNA from the Uganda and Zimbabwe cohort was extracted from peripheral
blood mononuclear cells (PBMCs) using the QIAmp DNA mini kit (Qiagen, cat#: 51306).
All genomic DNA was processed for integration site analysis and sequenced using the
Illumina MiSeq platform. Genomic DNA was digested with the restriction enzyme MseI
overnight at 37°C. Digested DNA was column purified with the Gel/PCR DNA Fragments
Kit (Geneaid, cat#: DF100) according to manufacturer’s instructions. Next, compatible
double-stranded linkers to the MseI sites were prepared as follows: MseI Linker (+)
5’GTAATACGACTCACTATAGG GCTCCGCTTAAGGG AC 3’and MseI Linker (-): 5’
[Phos]-TAGTCCCTTAAGCG GAG-[AmC7-Q] 3’ were mixed (20µl MseI Linker (+) [40
µM] and 20 µl MseI Linker (-) [40 µM]). The linker mixture was denatured for 5 min at
90°C and cooled 1°C every 3 min until the temperature reached 20°C using the T100 TM
Thermal Cycler (Bio-Rad). The prepared linkers are now referred to as the “adapter mix”.
Purified DNA was combined with the adapter mix at 21°C for about 14 hours with 13.5µl
of MseI digested samples, 3.5µl of adapter mix, 1µl of T4 DNA Ligase (400U/µl, [NEB,
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cat#: M0202S), and 2 µl of 10x ligase buffer. Subsequently, 20µl of the ligated sample was
digested at 37°C for 4 hours with 2µl of DpnI (20U/µl), 2µl of NarI (5U/µl), 5µl of 10x
buffer and water to a total volume of 50µl. Following digestion, the samples were column
purified. The junctions between the integrated HIV-1 LTR sequence and adjacent genomic
sequence were amplified in two separate rounds of PCR amplification.
The HIV-1 NL4-3 LTR sequence was used to design primers that amplify through the HIV1 LTR. The RuparLTR (Forward) 5’-TGCTTCAAGTAGTGTGTGC-3’ primer that
anneals to the HIV-1 LTRs and the Linker1 (Reverse) 5’-GTAATACGACTCACTATAG
GGC-3’primer specific to the MseI linker sequences were used for the first round of PCR
amplification. Each PCR reaction mixture consisted of 15.5µl sterile water, 5µl of
NarI/DpnI digested sample, 2.5µl of 10x Advantage 2 PCR Buffer, 0.5 µl of 15µM of
Linker1 primer , 0.5 µl of 15µM RuparLTR primer, 0.5µl of 10mM dNTPs and 0.5 µl of
50X Advantage 2 PCR polymerase mix (Takara Bio Inc., cat#:639201). PCR was run on
T100TM Thermal Cycler (Bio-Rad) under the following cycling conditions: 1 min at 94°C,
5 cycles of 2 sec at 94°C, 1 min at 72°C with an additional 20 cycles of 2 sec at 94°C, 1
min at 67°C and a final extension cycle for 1 min at 72°C and a 4°C hold. The second
round of nested PCR amplification was performed using the amplified sample from the
first round of PCR amplification. The PCR reaction mixture and cycling conditions were
as described for the first round of PRC amplification. The following primer set was used
for nested PCR: Rupar-LTR2nested (Forward) 5’-CTCTGGTAACTAGAGATCCCTCA
GAC C-3’ and Linker2nested (Reverse) 5’-AGGGCTCCGCTTAAGGGAC-3’. Next,
Illumina adapter overhang nucleotide sequences were added to the HIV-1 LTR sequence
and the MseI linker sequence by PCR amplification using the following primers: IllutagForward 5’-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTCTGGTAACT
AGAGATCCCT CAGAC C-3’and Illutag-Reverse 5’-TCGT CGGCAGCGTCAGATGT
GTATAAGAGACAGA GGGCTCCGC TTAAGGGAC-3’. Underlined section of the two
Illutag primers represent the overhang section. Illumina adapters were utilized in a PCR
reaction mixture containing 15.5µl sterile water, 5µl of nested PCR samples, 2.5µl of
Advantage 2 PCR Buffer (10x), 0.5 µl of Forward adapter (10µM), 0.5 µl of Reverse
adapter (10µM), 0.5µl of dNTPs (10mM) and 0.5 µl of 50X Advantage 2 PCR polymerase
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mix. PCR was run on T100TM Thermal Cycler (Bio-Rad). Cycling conditions were as
described for the first round of PRC amplification.
The PCR products were purified with AmPure XP beads (Beckman Coulter, cat#: A63881)
and the DNA samples were processed using the Nextera XT Index Kit (Illumina). The
Nextera XT Indexes technology utilizes a single tagmentation reaction that fragments and
tags input DNA with unique adapter and index (barcodes) sequences on both ends of the
DNA as previously described 30. The DNA samples were purified using AmPure XP beads
following addition of the barcodes. The barcoded samples were quantified using the Quantit PicoGreen dsDNA Assay Kit (Invitrogen, cat#: P7589). The absorbance of the plates
were read (excitation 480nm for 10 sec and emission 540 nm for 10 sec) with the Cytation5
Imaging Reader (BioTek) and the Gen5 3.02.1 analysis software. Sample concentration
was determined by standard curve assessment. The barcoded samples was sequenced
through Illumina MiSeq using 2 × 150 bp chemistry at the London Regional Genomics
Centre /Robarts Research Institute from Western University (Canada) and at Case Western
Reserve University (USA).

3.2.3

HIV-1 integration site library and computational analysis

Genomic DNA was processed for integration site analysis and sequenced using the
Illumina MiSeq platform as described

30,57

. Fastq sequencing reads were quality trimmed

and unique integration sites identified using our in-house bioinformatics pipeline 30, which
is now called the Barr Lab Integration Site Identification Pipeline (BLISIP version 2.9).
BLISIP version 2.9 includes the following updates: bedtools (v2.25.0) which is used to
compute distances between integration sites and genomic features, bioawk (awk version
20110810) a programming language for biological data manipulation, bowtie2 (version
2.3.4.1) is used for aligning sequence reads to the human genome, and restrSiteUtils
(v1.2.9) is used to generate in silico matched random control integration sites based on
restriction enzyme used or DNA shearing method. HIV-1 LTR-containing fastq sequences
were identified and filtered by allowing up to a maximum of five mismatches with the
reference NL4-3 LTR sequence and if the LTR sequence had no match with any region of
the human genome (GRCh37/hg19). Integration site profile heatmaps were generated using
our in-house python program BHmap (BHmap version 1.0). Sites that could not be
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unambiguously mapped to a single region in the genome were excluded from the study.
Mapping of integration sites to non-B DNA motifs was performed using the Non-B DB for
the human genome (GRCh37/hg19) as previously described

58, 59

. LADs were retrieved

from http://dx.doi.org/10.1038/nature06947 60.

3.2.4

Datasets

All integration site datasets used in this study were independently analyzed using BLISIP
version 2.9 and BHmap version 1.0. Integration site datasets from patients infected with
HIV-1 subtype B, were obtained from the Cohn dataset and Maldarelli/Wu dataset. Cohn
dataset was obtained within the National Center for Biotechnology Information Sequence
Read Archive (NCBI SRA) using the accession number SRP045822 as described 61. The
Maldarelli/Wu dataset was obtained from the supplemental material as described

62

.

Identical integration sites in each dataset were collapsed into one unique site for the
analysis. Integration site datasets from in vitro infection of HIV-1 subtype B were obtained
from published datasets (Supplemental Table 3.1)

15,20,23,26,63,64

. Integration site datasets

for SIV, FIV, HTLV-1, MLV, MMTV, FV and endogenous retroviruses (ERVs) were
obtained from several published datasets (Supplemental Table 3.1) 15,17–20,23,65–69.

3.2.5

Statistical analysis

Fisher’s exact test was used for all comparisons of integration site distributions and using
Graphpad Prism v6.0. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

3.3
3.3.1

Results
Evolutionarily divergent retroviruses exhibit distinct
preferences for integration into the genome.

Previous analyses of integration sites for multiple retroviruses have shown that integration
is more or less likely to occur in or near certain genomic features. However, the integration
site profiles of these evolutionarily diverse retroviruses with respect to non-B DNA is
unknown. To determine if different retroviruses display a distinct integration profile with
respect to non-B DNA motifs, we analyzed the integration sites from previously published
datasets using viruses from the lentivirus (e.g. HIV-1, SIV and FIV), deltaretrovirus (e.g.

121

HTLV-1), the gammaretrovirus (e.g. MLV), the spumavirus (e.g. FV), the alpharetrovirus
(e.g. ASLV) and the betaretrovirus (e.g. MMTV) genera (Supplemental Table 3.1). We
also analyzed the integration site profiles of endogenous retroviruses (ERVs) naturally
found within the human genome. Integration sites from all datasets were obtained from
various human cell lines and primary cells, such as HEK 293 T, HeLa, Jurkat and primary
CD4+ T cells as shown in (Supplemental Table 3.1). To ensure a comprehensive
comparative analysis of integration site profiles using the same human genome annotation,
we utilized hg19 for our analyses. We also used our previously developed in-house
bioinformatics pipeline called the Barr Lab Integration Site Pipeline (BLISIP) to generate
integration site profiles from the different retroviral integration site datasets

57,30

. Our

analyses involved unique integration site events and excluded sites arising from clonal
expansion, sites falling in repeat regions or regions that cannot be confidently placed on a
specific chromosome (e.g. ChrUn). Enrichment of integration sites within genomic
features was determined by comparing the proportion of sites with either a matched random
control (MRC) to account for restriction site bias in the cloning procedure during library
construction and for comparison of datasets that used DNA shearing/fragmentation during
library construction (Supplemental Table 3.1). To further validate our in-house
bioinformatics analysis pipeline (BLISIP), and to provide a direct comparison of the
integration site profiles of evolutionarily diverse retroviruses, we analyzed previously
published integration site datasets using BLISIP. Integration sites in several common
genomic features were quantified and placed in four distance bins starting from within each
genomic feature (Bin 0) to > 50,000 base pairs (bp) away from the feature (Bin 4).
Heatmaps from each retrovirus showing the fold enrichment and fold depletion of sites in
each bin compared to MRC are shown in Figure 3.1A. Heatmaps are superimposed on a
phylogenetic tree constructed using reverse transcriptase sequences to show the
evolutionary relatedness of the different retrovirus genera 70.
Consistent with previous studies, HIV-1, SIV and FIV integration sites are highly enriched
within genes (64%, 84%, 90% respectively) and are present at levels significantly more
than that expected by chance (P < 0.0001, Fisher’s exact test) (Figure 3.1A, 3.1B and
Supplemental Table 3.2) 18,71,17.
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Figure 3.1: Evolutionarily divergent retroviruses exhibit distinct preferences for
integration into the genome. (A) Heatmap depicting the fold enrichment or depletion of
integration sites in common genomic features compared to the matched random control
(MRC). Darker shades represent higher fold-changes in the ratio of integration sites to
MRC sites. Asterisks within each heatmap (*P < 0.05; **P < 0.01; ***P < 0.001; ****P <
0.0001, Fisher’s exact test) represent significant differences in the number of integration
sites in different retroviruses compared to MRC. Bins represent the distance of the
integration sites from the genomic feature. Bin 0 = within the feature, Bin 1= 1 - 499 bp;
Bin 2 = 500 -4,999 bp; Bin 3 = 5,000-49,999 bp; Bin 4 = < 49,999 bp. Infinite number
(inf), 1 or more integrations were observed when 0 integrations were expected by chance.
Not a number (nan), 0 integrations were observed and 0 were expected by chance. (B)
Proportion of unique HIV-1 integration sites in common genomic features. Blue lines
represent MRC values. Significant differences are with respect to the paired MRC (blue
lines) and are denoted by asterisks (Fisher’s exact test; *P < 0.05; **P < 0.01; ***P <
0.001; ****P < 0.0001). HIV-1 = human immunodeficiency virus, SIV = simian
immunodeficiency virus, FIV= feline immunodeficiency virus, HTLV-1= human Tlymphotrophic virus 1, MLV = murine leukemia virus, FV = foamy virus, ASLV = avian
sarcoma leukosis virus, MMTV = mouse mammary tumor virus and ERVs = endogenous
retroviruses. The number of unique integration sites for each retrovirus are as follow: HIV1 = 180699 sites SIV = 160 sites, FIV= 226 sites, HTLV-1= 624 sites, MLV = 1484 sites,
FV = 3423 sites, ASLV = 680 sites, MMTV = 268 sites and ERVs = 325 sites.
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Figure 3.1

Figure 3.1: Evolutionarily divergent retroviruses exhibit distinct preferences for integration into the genome.
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Figure 3.1

Figure 3.1: Evolutionarily divergent retroviruses exhibit distinct preferences for
integration into the genome.
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Our analysis of HTLV-1, ASLV and MLV also agreed with previous reports, confirming
that these viruses exhibit only modest preferences for integration within genes (54%, 56%
and 56% of integration sites found within genes respectively) (Figure 3.1A and 3.1B,
Supplemental Table 3.2) 16, 72.
In contrast, MMTV, FV and ERVs showed no preference for integration into genes (47%,
43% and 32% respectively), with FV and ERVs showing a significant disfavoring for
integration into genes (P < 0.001, Fisher’s exact test). All retroviruses showed no
preference for integration directly into transcription start sites (TSS). Notably, all
retroviruses showed enriched integration near TSS. This was particularly noteworthy for
FV and MLV, which showed a strong preference for integration near (<5,000 bp) TSS
(25% and 34% respectively), which was 2- to 3-fold (respectively) more than that expected
by chance (P <0.0001, Fisher’s exact test) (Figure 3.1A, Supplemental Table 3.2).
We further observed that all exogenous retroviruses and ERVs integrated near CpG islands
except for MMTV, which showed no preference for integration in or near CpG islands.
Additionally, FV and MLV also showed a strong preference for integration in and near
(<500 bp) CpG islands (7% and 10%), which was 2- to 11 fold (respectively) more than
that expected by chance (P <0.0001, Fisher’s exact test) (Figure 3.1A, Supplemental
Table 3.2). Repetitive elements, such as long interspersed nuclear elements (LINEs), short
interspersed nuclear elements (SINEs), ERVs (retrotransposons), satellite DNA, simple
repeats (microsatellites), and low-complexity repeats (LCR) account for nearly half of the
human genome sequence. However, no preference for integration into these regions was
observed for any of the retroviruses except for HIV-1 and FV which targeted SINEs, and
FV and HTLV-1 which targeted satellite DNA (Figure 3.1A).
The nuclear architecture is known to influence HIV-1 integration site selection and proviral
expression

60,73

. HIV-1 strongly disfavors integration into heterochromatic condensed

regions positioned in lamin-associated domains (LADs) at the nuclear periphery, although
some integration does occur in these regions and significantly influences expression of
latent proviruses

74

. We asked whether other retroviruses also disfavor integration into

LADs. Like HIV-1, most retroviruses strongly disfavored integration into LADs with only
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11-28% of sites falling within LADs (P < 0.0001, Fisher’s exact test) (Figure 3.1A,
Supplemental Table 3.2). In contrast, 48% of MMTV and 44% of ERV integration sites
were located in LADs and were significantly more than that expected by chance (P < 0.016,
Fisher’s exact test). Together, these data confirm and extend previous findings that
retroviruses of diverse genera have different preferences for integrating into common
genomic features. Furthermore, these data indicate that most retroviruses avoid integrating
into transcriptionally inactive heterochromatin, except MMTV and ERVs, which exhibit a
strong preference for heterochromatin.

3.3.2

Evolutionarily diverse retroviruses target non-B DNA for
integration.

Non-B DNA motifs are new host factors we previously identified that influence lentiviral
integration and serve as important integration site targets for HIV-1 30 (also see chapter 2).
However, their influence on integration site targeting for other retroviruses was previously
unknown. We analyzed several published integration site datasets from evolutionarily
diverse retroviruses (Supplemental Table 3.1) to obtain and compare their non-B DNA
integration site profiles. All retroviral integration sites were located in or within <500 bp
of non-B DNA, with strong preference for certain non-B DNA motifs (Figure 3.2).
Notably, HTLV-1 and FV were the only two retroviruses that exhibited an enrichment of
sites directly in the majority of non-B DNA motifs compared to MRC (Figure 3.2 and
Supplemental Table 3.3). Some other notable preferences for non-B DNA include HTLV1, which showed a significant enrichment of integration sites directly in and/or near Aphased motifs (P < 0.05, Fisher’s exact test), cruciform motifs (P < 0.05, Fisher’s exact
test) and inverted repeats (P < 0.01, Fisher’s exact test). FV showed significant enrichment
in and adjacent (<50 bp) to G4 motifs (P < 0.001, Fisher’s exact test) and Z-DNA motifs
(P < 0.05, Fisher’s exact test). MLV showed strong enrichment of sites near G4 motifs,
triplex motifs and Z-DNA motifs. ASLV strongly favored integration near slipped and
triplex motifs. MMTV showed a strong preference for short tandem repeats, slipped motifs
and triplex motifs.
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Figure 3.2: Evolutionarily diverse retroviruses target non-B DNA for integration.
Distribution of unique retroviral integration sites in non-B DNA-forming motifs. Darker
shades represent higher fold-changes in the ratio of integration sites to matched random
control (MRC) sites. Asterisks within each heatmap (*P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001, Fisher’s exact test) represent significant differences in the number of
integration sites in different retroviruses compared to MRC. HIV-1 = human
immunodeficiency virus, SIV = simian immunodeficiency virus, FIV= feline
immunodeficiency virus, HTLV-1= human T-lymphotrophic virus 1, MLV = murine
leukemia virus, FV = foamy virus, ASLV = avian sarcoma leukosis virus, MMTV = mouse
mammary tumor virus and ERVs = endogenous retroviruses. The number of unique
integration sites for each retrovirus are as follow: HIV-1 = 180699 sites SIV = 160 sites,
FIV= 226 sites, HTLV-1= 624 sites, MLV = 1484 sites, FV = 3423 sites, ASLV = 680
sites, MMTV = 268 sites and ERVs = 325 sites.
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Figure 3.2: Evolutionarily diverse retroviruses target non-B DNA for integration.
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SIV and FIV both exhibited strong preferences for integration near inverted repeats, mirror
repeats and short tandem repeats, although SIV preferred to integrate closer to these nonB DNA than FIV. FIV and SIV also strongly disfavored integration in or near G4 motifs.
ERVs exhibited a strong enrichment of sites near triplex motifs. HIV-1 showed significant
enrichment of sites directly in G4 motifs and short tandem repeats, and 150-500 bp away
from all non-B DNA motifs except A-phased motifs. Taken together, these data show that
all retroviruses exhibit distinct non-B DNA integration site profiles, but also share similar
strong preferences for integration into specific non-B DNA motifs.

3.3.3

Integration site profiles differ between in vitro-derived and
patient-derived datasets

HIV-1 infection is the most clinically prevalent retroviral infection in the human
population, yet most integration site analyses have been performed using HIV-1/vector
infections performed in vitro using cell lines 27. To determine if the HIV-1 integration site
profiles from acute HIV-1 infections of cell lines (in vitro-derived infections) differ from
those from chronically infected individuals (patient-derived) , we analyzed and compared
the integration sites from previously published datasets (Supplemental Table 3.1, Figure
3.3). We first analyzed the integration site profiles with respect to several commonly
studied genomic features. A total of 9 previously published datasets were used to evaluate
the in vitro-derived (13,601 sites) and patient-derived sites (167,098 sites). We first
investigated the integration site profile with respect to several commonly studied genomic
features. In general, the integration site profiles were similar with some notable differences.
Both in vitro and patient datasets strongly favored integration in genes (83% in vitro, 62%
in patients, P < 0.0001, Fisher’s exact test) (Figure 3.3A, 3.3B and Supplemental Table
3.4). Compared to the in vitro dataset, integration sites in the patient dataset were
significantly enriched in CpG islands, DNaseI hypersensitivity sites, ERVs, LADs, satellite
DNA, simple repeats and SINEs (P < 0.0001, Fisher’s exact test). In contrast, integration
sites in the patient dataset were significantly depleted in LINEs and low complexity repeats
compared to the in vitro dataset (P < 0.0001, Fisher’s exact test). We also identified
differences in integration site targeting preferences for non-B DNA motifs between the two
datasets.
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Figure 3.3: Integration site profiles differ between in vitro-derived and patientderived datasets. (A) Heatmaps illustrating the distribution of unique integration sites in
common genomic features for HIV-1 in vitro (n= 13601sites) and infected patients datasets
(n= 167098 sites). Darker shades represent higher fold-changes in the ratio of integration
sites to matched random control (MRC) sites. Numbers within each heatmap represent the
fold-increase or decrease in the number of unique integration sites in patient-derived
dataset or in vitro-derived dataset compared to the MRC. Integration sites of patientderived dataset were also compared to in vitro-derived dataset. (B) Percentage of unique
HIV-1 integration sites directly within common genomic features in in vitro-derived
dataset or patient-derived dataset. (C) Heatmaps depicting the fold enrichment or depletion
of integration sites in non-B DNA motifs compared to the MRC. (D) Percentage of unique
HIV-1 integration sites directly within non-B DNA motifs (G4, triplex and Z-DNA motifs)
in in vitro-derived dataset or patient-derived dataset. All significant differences are
denoted by asterisks (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001) and were
determined by Fisher’s exact test.
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Figure 3.3: Integration site profiles differ between in vitro-derived and patientderived datasets.
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When compared to the MRCs, integration sites in the patient dataset were enriched directly
in G4 motifs and short tandem repeats, whereas these features were disfavored in the in
vitro dataset (Figure 3.3C and Supplemental Table 3.4). Integration sites in the patient
dataset were also highly enriched in a region 150 to 500 bp away from all non-B DNA
motifs except A-phased motifs compared to the in vitro dataset. Notably, when the patient
dataset was compared to the in vitro dataset, significant enrichment was observed within
500 bp of G4, triplex and Z-DNA motifs (Figure 3.3C, 3.3D and Supplemental Table
3.4). Together, these data show striking differences in integration site targeting preferences
between in vitro-derived and patient-derived datasets.

3.3.4

HIV-1 subtypes A, B, C and D have different integration site
preferences.

To our knowledge available integration site studies have only been conducted with HIV-1
subtype B, which only represents ~10% of the infections worldwide. As of today, much
less is known on the integration site profile of other HIV-1 subtypes. We asked if the
integration site profiles from individuals infected with HIV-1 non-subtype B virus are
similar to those infected with subtype B virus.
Genomic DNA was isolated from peripheral blood mononuclear cells (PBMCs) from a
cohort of women in Uganda and Zimbabwe infected with HIV-1 subtypes A, C or D and
used to generate integration site libraries (Supplemental Table 3.5 A). Integration site
profiles were generated from a total of 48 infected females (16 subtype A, 19 subtype C
and 13 subtype D) and compared to the integration site profile from 14 men and women
infected with subtype B virus generated from previously published datasets (Supplemental
Table 3.5 B and C). The number of integration sites analyzed in this study were: subtype
A, 429 sites; subtype B, 139480 sites; subtype C, 484 sites; and subtype D, 323 sites.
Integration sites from all HIV-1 subtype viruses were highly enriched in genes (Figure 3.4
A, B and Supplemental Table 3.6). Notably, subtypes A, C and D exhibited a significantly
stronger preference for integrating into genes compared to subtype B (A: 82%, C: 71%, D:
78% and B: 63%) (Figure 3.4 B and Supplemental Table 3.6).

Integration was

disfavored in CpG islands for each subtype; however, sites were enriched in a region 5005,000 bp away from CpG islands for each subtype. Integration sites for subtypes B, C and

133

D were enriched in and near DHS, whereas subtype A sites were only enriched near (1-500
bp) this feature. Subtypes A and C exhibited enriched integration in low complexity
repeats, whereas these regions were disfavored by subtypes B and D. Subtypes A, C and
D disfavored integration in or near satellite DNA, whereas subtype B favored integration
near (1-5,000 bp) satellite DNA. Integration in or near LADs was strongly disfavored in
all subtypes.
Next, we analyzed the integration site profiles from the same datasets with respect to nonB DNA motifs. Integration sites falling directly within non-B DNA motifs or in distance
bins of 50 bp up to 500 bp away from each motif were quantified. As shown in Figure 3.4
C and Supplemental Table 3.7, the integration site profiles differed substantially among
the different subtypes, especially when compared to subtype B. The most notable
difference in integration site preference among the different subtypes was towards G4
motifs. Subtype B virus favored integration directly in and near (150-500 bp) G4 motifs.
Subtypes A, C and D generally disfavored integration in or near G4 motifs, except in a
region 100-150 bp away from the motif where integration was favored. Like subtype B,
subtype A also favored integration directly in the G4 motif itself. Some other notable
differences were as follows. Subtypes A and C exhibited strong preferences for integration
near A-phased motifs, whereas subtypes D and B showed little to no preference for these
motifs.
All subtypes favored integration near cruciform motifs, with non-subtype B viruses
exhibiting a stronger preference for these motifs than subtype B virus. All subtypes favored
integration 150-500 bp away from direct repeats, with subtypes A, C and D also favoring
integration adjacent (1-50 bp) to direct repeats All subtypes favored integration near
slipped motifs, with subtype B only favoring a region 150-500 bp away from these motifs.
Similar to its preference for slipped motifs, subtype B virus favored integration in triplex
motifs and Z-DNA motifs in a region 150-500 bp away from these features. Non-subtype
B viruses showed little preference for slipped or Z-DNA motifs; however, subtypes A and
D favored integration in defined regions within 500 bp from these motifs (Figure 3.4 C).
In contrast, subtype C virus showed very little preference for triplex or Z-DNA motifs.
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Figure 3.4: HIV-1 subtypes A, B, C and D have different integration site preferences.
(A) Heatmaps showing unique integration sites distribution of HIV-1 subtypes A, B, C and
D in common genomic features compared to the matched random control (MRC). Darker
shades represent higher fold-changes in the ratio of integration sites to matched random
MRC sites. Numbers within each heatmap show the fold-increase or decrease in the
number of unique integration sites in HIV-1 subtypes A, B, C, and D compared to MRC.
Not a number (nan) indicates that 0 integrations were observed and 0 were expected by
chance. (B) Proportion of integration directly within genes for subtypes A, B, C and D. (C)
Distribution of unique integration sites for of HIV-1 subtypes A, B, C and D in non-B DNA
motifs compared to MRC. Darker shades represent higher fold-changes in the ratio of
integration sites to matched random MRC sites. Numbers within each heatmap show the
fold-increase or decrease in the number of unique integration sites in HIV-1 subtypes A,
B, C, and D compared to the MRC. All significant differences were determined by Fisher’s
exact test and are denoted by asterisks (*P < 0.05; **P < 0.01; ***P < 0.001; ****P <
0.0001). Number of integration sites are as follow: HIV-1 subtype A = 429 sites; HIV-1
subtype B = 139480 sites; HIV-1 subtype C = 484 sites; and HIV-1 subtype D = 323 sites.
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Figure 3.4: HIV-1 subtypes A, B, C and D have different integration site preferences.
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Overall, integration preferences were most similar between non-subtype B and subtype B
viruses for inverted repeats, mirror repeats and short tandem repeats, which all showed
enrichment near these features. Together, these data show that the integration site profiles
from HIV-1 subtype A, C and D infections differ substantially from subtype B infections.
Moreover, each subtype exhibits a distinct integration site bias for specific genomic
features, particularly non-B DNA motifs.

3.3.5

Combination antiretroviral therapy (cART) alters HIV-1
integration site selection in common genomic features

Once infected individuals start receiving cART to control HIV-1 replication, infected cells
bearing silent proviruses becomes highly selected for with treatment. Given that cART
helps select for integration into silent regions such as intergenic regions that can maintain
latency 61, we further investigated the association between treatment and HIV-1 integration
site selection among different HIV-1 subtypes, including with respect to non-B DNA.
Unique integration sites from individuals infected with either HIV-1 subtype A, C, D and
B were grouped into untreated (not receiving cART) and treated populations/samples
(receiving cART) (Supplemental Table 3.5 A, B, and C). All integration sites were
compared to MRC. Interestingly, cART treatment lead to a decrease in frequency into
genes for subtypes B (67% untreated, 62% treated) and C (73% untreated, 55% treated)
(Figure 3.5, Supplemental Table 3.8) compared to MRC. cART did not induce a
significant change in the frequency of integration into genes for subtype A (82% untreated,
84% treated), D (79% untreated , 77% treated). Integration within endogenous retroviruses
(ERVs), satellite DNA and lamina associated domains (LADs) remained strongly depleted
in the untreated and treated groups of each subtype. Integration directly into CpG islands
was highly enriched in the untreated subtype B population compared to the treated
population, which showed a reduction in CpG island integration (P < 0.001). In contrast to
other subtypes, subtype B showed a strong preference for integration directly within
DNaseI hypersensitivity sites and SINEs for both untreated and treated samples. However,
subtypes C and D showed enriched integration within DnaseI hypersensitive sites in the
untreated group compared to the treated group (Figure 3.5).
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Figure 3.5: Combination antiretroviral therapy (cART) alters HIV-1 integration site
selection in common genomic features. Heatmaps illustrating the distribution of unique
integration sites in common genomic features for HIV-1 subtype A, B, C and D untreated
and treated patients’ samples. Integration sites were compared to matched random control
(MRC). Darker shades represent higher fold-changes in the ratio of integration sites to
MRC sites. Numbers within each heatmap show the fold-increase or decrease in the
number of unique integration sites in untreated and treated HIV-1 subtypes A, B, C, and D
compared to the MRC. Not a number (nan), 0 integrations were observed and 0 were
expected by chance. Significant differences were determined by Fisher’s exact test and are
denoted by asterisks (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Number of
sites are as follow: Subtype A untreated = 259 sites, Subtype A treated = 170 sites,
Subtype B untreated = 27077, Subtype B treated = 112403 sites, Subtype C untreated =
448 sites, Subtype C treated = 36 sites, Subtype D untreated = 156 sites and Subtype D
treated = 167 sites.
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Figure 3.5: Combination antiretroviral therapy (cART) alters HIV-1 integration site selection in common genomic features.
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Overall, these data strongly suggest that cART alters HIV-1 integration site target selection
by favoring or disfavoring certain features among the different subtypes.

3.3.6

cART and HIV-1 integration site selection in non-B DNA
motifs

Next, we further evaluated the frequency of integration sites in untreated and treated
samples from subtypes A, B, C and D with respect to non-B DNA motifs using the same
datasets as in Supplemental Table 3.5 A, B and C. Integration sites were quantified either
directly within non-B DNA motifs or in distance bins of 50 bp up to 500 bp away from
each motif. In the case of non-B DNA motifs, subtype B showed enriched integration 50499bp from the motifs for both untreated and treated patient samples. A similar enrichment
was observed in the other subtypes (Figure 3.6, Supplemental Table 3.9). Notably,
integration in or near A-phased motif was significantly depleted in subtype B and enriched
in subtypes A, C and D.
Since certain non-B DNA motifs such as G4 and Z-DNA can inhibit gene expression, we
further assessed whether patients receiving cART had enriched integration into those
motifs. We observed that all subtypes targeted G4 motifs at a distance of 100-149 bp for
both untreated and treated group except for subtype B, which showed no preference for
integration (untreated and treated samples) at that distance compared to other subtypes.
Most important, we observed a 3 fold and 12 fold enrichment in the treated groups for
subtype A and C respectively (Figure 3.6). In contrast, no substantial change in integration
near G4 (100-149 bp from G4) was observed for subtype D between the untreated and
treated group. These results again indicate that cART alters integration site targeting of
non-B DNA motifs.

3.4

Discussion

The analysis presented here showed that non-B DNA motifs, which are novel features that
influence HIV-1 integration, are also targeted by other retroviruses. Specifically,
evolutionarily diverse retroviruses exhibit distinct non-B DNA integration site profiles, but
also share similar strong preferences for integration into several non-B DNA motifs.
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Figure 3.6: cART and HIV-1 integration site selection in non-B DNA motifs.
Heatmaps showing the distribution of unique integration sites for HIV-1 subtypes A, B,
C, D untreated and subtype A, B, C and D treated patients samples in non-B DNA motifs.
Integration sites were compared to matched random control (MRC). Darker shades
represent higher fold-changes in the ratio of integration sites to MRC sites. Numbers within
each heatmap show the fold-increase or decrease in the number of unique integration sites
in untreated and treated HIV-1 subtypes A, B, C, and D compared to the MRC. Not a
number (nan), 0 integrations were observed and 0 were expected by chance. Significant
differences were determined by Fisher’s exact test and are denoted by asterisks (*P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001). Subtype A untreated = 259 sites, Subtype A
treated = 170 sites, 27077, Subtype B treated = 112403 , Subtype C untreated = 448
sites, Subtype C treated = 36 sites, Subtype D untreated = 156 sites and Subtype D treated
= 167 sites.
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Figure 3.6: cART and HIV-1 integration site selection in non-B DNA motifs.
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We also showed that most retroviruses disfavored integration into transcriptionally inactive
heterochromatin, except MMTV and ERVs which exhibit a strong preference for
heterochromatin. We further demonstrated striking differences in integration site targeting
preferences between in vitro-derived and patient-derived datasets and showed that
enrichment of HIV-1 integrations in and/or near non-B DNA motifs that regulate gene
expression is specific to patient datasets. Our data also shows that HIV-1 subtype A, C and
D infections differ substantially from subtype B infections and that cART alters integration
site targeting of non-B DNA.
Our analyses are consistent with previous studies and extend this work to show that
additional diverse retroviruses genera have different preferences for integrating into
common genomic features, such as genes and near transcription start sites and CpG islands.
Specifically, we were able to confirm that HIV-1, SIV and FIV strongly favored integration
in genes, while HTLV-1, ASLV and MLV, viruses exhibited only modest preferences for
integration into genes

16 ,72,

. However, MMTV, FV and ERVs disfavored integration into

genes. It is important to note that our analysis showed a slightly higher percentage of
integration into genes by HTLV-1, ASLV and MLV (54%, 56% and 56% respectively)
than previously reported (HTLV 46.8% , ASLV 46.4% or 40%, and MLV 45.7% or
40.2%) 19, 22. In our study, we used an earlier version of the UCSC genome database and
RefSeq genes human gene annotation, which might be larger than the assembly previously
used by others. This may have correlated to the slightly higher values seen in our current
study. Overall, our results are consistent with previous findings. Factors that may influence
integration site selection might include variation in the properties of their integrase
proteins. In fact, previous phylogenetic analysis that looked at the integrase sequences of
different retroviruses showed clustering among certain retroviruses, where HIV-1, SIV and
FIV were found in the same cluster and MLV and FV in the same cluster

19

. This may

contribute to why certain retroviruses showed similar integration site preferences with
respect to specific genomic features. Nonetheless, properties of the pre-integration
complex and virus interaction with cellular host factors and chromosomal DNA might also
be critical in determining proviral integration site selection.
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Our analysis of integration site selection also showed that non-B DNA motifs are not
targeted only by HIV-1. Other retroviruses targeted non-B DNA motifs for integration and
exhibited distinct integration site preference with respect to non-B DNA. While most
integration occurred within the majority of the motifs for HTLV-1 and FV, HIV-1 showed
integration spanning 150-500 bp away from each motif. Thus, integration targeting for
other retroviruses seems to not occur at specific distances for the most part. The integration
events seen in the other retroviruses (e.g. SIV, FIV, MLV, ASLV and MMTV) might
suggest the lack of cellular factors capable of interacting with their viral integrase and/or
pre-integration complex that could help direct their integration into specific distances from
non-B DNA motifs. Importantly, HIV-1 integrase is known to bind directly to certain nonB DNA motifs

75–84

. Therefore, this could facilitate and consistently direct integration

within a specific distance from non-B DNA motifs. Like HIV-1 SIV, FIV, MLV, ASLV
and MMTV, also targeted certain non-B DNA motifs such as G4 motifs and Z-DNA, which
had substantial implications in regulating nearby gene expression and potentially proviral
gene expression. Notably, on one hand, interaction of non-B DNA structures with their
specific transcription factors can induce transcriptional activation 85–88. On the other hand,
the three dimensional structure of non-B DNA motifs can prevent binding of B-DNAspecific transcription factors, leading to suppression of adjacent genes

89–92

. Thus, non-B

DNA motifs can play a substantial role in regulating gene expression of all exogenous
retroviruses, including HIV-1.
Historically, most of the conclusions regarding HIV-1 integration site targeting preferences
were made in vitro using HIV-1 vectors and cell lines. We showed here that there are
profound differences in integration site targeting preferences between in vitro-derived and
patient-derived integration site datasets. Notably, sites in the patient dataset were highly
enriched in a region spanning 150 to 500 bp away from most non-B DNA motifs compared
to the in vitro dataset. It is unclear what causes these differences in integration as related
specifically to non-B DNA. However, it could be suggested that integration sites studies
from in vitro experiments are usually associated with acute short term infection, therefore,
representing integration sites during the early stages of infection. In contrast, integration
sites from patients are associated with chronic and persistent infection where some cells
are productively infected while many cells also undergo latency, especially when receiving

145

antiretroviral treatment. As a result, integrations from patient data may be biased towards
genomic sites that are more favorable for both HIV-1 expression (e.g. genes) and latency
(e.g. non-B DNA motifs). Most importantly, HIV-1 integration in patient-derived datasets
was significantly enriched near G4 motifs, as opposed to the cell line dataset which did not
target G4 motifs. However, integration near other non-B DNA motifs also occurred,
including integration near G4 motifs, which is relevant due to its role in gene regulation.
From these results, it is clear that distinct integration site biases exist between in vitroderived and patient-derived datasets. As such, generalizations regarding HIV-1 integration
site preferences cannot be made solely from either in vitro-derived or patient-derived
datasets. Additionally, the majority of in vitro studies are conducted in cancer derived cell
lines that do not reflect the normal cell types infected by HIV-1. Importantly, these cells
may lack of the expression of integrase cofactors as well as having abnormal chromatin
structure.
Genetic variation between subtypes can range between 25 to 35%

49

. Importantly, the

genetic differences between subtypes may influence their interaction with the host,
therefore also influencing disease transmission, progression and notably integration site
selection. Here, we have shown similar integration preference with respect to commonly
studied genomic features such as genes, CpG islands, satellite DNA and LAD among
subtypes A, B, C and D. However, substantial differences were observed among the
different subtypes with respect to non-B DNA motifs. Notably, it is unclear why subtype
B is the only subtype that showed enriched integration within specific distances from nonB DNA compared to other subtypes. Variation in integrase structure could contribute to
this difference in integration. In fact, natural polymorphisms in HIV-1 integrase have been
observed among different subtypes, which might affect their integration site selection 93,94.
Additionally, specific polymorphisms in HIV-1 integrase have been reported to retarget
integration away from gene dense regions, which correlated with increase disease
progression and virulence

95

. This further suggests that viral integrase can substantially

contribute to disease progression as it relates to the virus integration site targeting. Of
importance, we have also shown enriched integration between 100 -149 bp away from nonB DNA motifs, particularly G4 motifs, among subtypes A, C and D but not subtype B.
Integration at that distance may play an essential role in integration site selection and may
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be a result of G4 structure-induced repositioning nucleosomes, which are comprised of
~147 bp of DNA wrapped around a histone octamer core

96

. In fact, G4 motifs form in

nucleosome-free regions in the genome 97. As such, this ability to locally and dynamically
organize flanking nucleosomes may contribute to transcriptional regulation of adjacent
genes.
Upon cART initiation, infected cells bearing silent proviruses become highly selected for.
As cART helps select for integration into silent regions such as intergenic regions 31, it was
expected that integration site selection will also retain a strong bias toward heterochromatin
rich regions (e.g. satellite DNA and LADs) in cART treatment patients. Our results showed
enrichment in LADs in treated samples compared to untreated samples in subtype A, B and
D infections. This further supports the idea that cART selects for integration sites located
in heterochromatin among different subtypes. Notably, our observations indicated that
cART changed the integration profile for all subtypes. We also observed that subtypes A,
C and D shared higher similarity in integration site preferences compared to subtype B.
Additionally, cART lead to an enriched integration near G4 motifs, which are also found
in heterochromatin rich regions 90.
In conclusion, we identified distinct non-B DNA structures surrounding integration sites
that are targeted differentially by evolutionarily diverse retroviruses, including HIV-1 viral
subtypes. Additionally, different HIV-1 subtypes have distinct integration profiles that
differ before and after cART.
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Chapter 4

4

The quiescent/latent HIV-1 integration site landscape
from different anatomical tissues reveals unique
differences

HIV-1 infection persists in latently infected CD4+ T cells from peripheral blood despite
suppressive antiretroviral therapy. Additional anatomical sites harboring HIV-1 are also
key reservoirs that are established early during infection. Together, these sites present a
major barrier for HIV-1 eradication, where replication competent virus can persist, thus
restoring the latent reservoir upon cessation of antiretroviral therapy. Additionally, these
anatomical sites may help maintain a continuous low-level of viral replication despite
antiretroviral therapy. While the integration site selection of HIV-1 has been extensively
studied in peripheral blood from infected individuals, little is known about the integration
site distribution in other sanctuary/anatomical sites. Here, we compared the distribution of
integration sites of HIV-1 in the peripheral blood, the brain, and the gastrointestinal tract.
All anatomical sites exhibited a significant preference for integration in genes, as
previously observed in peripheral blood studies, with a somewhat lower frequency in the
brain. We also showed distinct integration profiles from the peripheral blood, the brain,
and the gastrointestinal tract with respect to non-B DNA motifs. Importantly, integration
site were strongly enriched in and/or near guanine-quadruplex (G4) motifs, a type of nonB DNA motif, which are known to suppress expression of adjacent genes. Our findings
demonstrate clinically favorable integration site profiles in anatomical sites of HIV-1
infected individuals and implicate non-B DNA motifs as an essential factor in HIV-1
integration within various latent reservoirs.

4.1

Introduction

Since the discovery of the human immunodeficiency virus type 1 (HIV-1) in the early
1980’s as the key ethological agent of acquire immunodeficiency syndrome (AIDS), more
than 35 million individuals have died from HIV-1/AIDS related illness

1,2,3,4

. The Joint

United Nations Programme on HIV and AIDS (UNAIDS) reported that in the year 2017
over 36 million people were currently living with HIV-1, with approximately 2 million
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new infections occurring annually 4. The use of combination antiretroviral therapy (cART)
has significantly improved the quality of life of infected individuals and has led to a
substantial reduction in morbidity and mortality related to HIV-1/AIDS infection 5. Despite
the use of cART, which helps reduce HIV-1 plasma viremia (viral load) below the
detectable limit (<50 copies of viral ribonucleic acid (RNA)/ml), no functional cure has
been achieved with cART 5. Upon cessation of cART, there is a rapid rebound in viremia
6

. Notably, the existence of a subset of transcriptionally silent/latent cells that can be

reactivated when treatment is discontinued has been detected in individuals on effective
cART 7,6,8. Multiple factors can contribute to cART failure such as the occurrence of drug
resistant virus during prolonged treatment

9

. However, the presence of latently infected

cells is a major obstacle for HIV-1 eradication 10,11. Latent reservoirs of infected cells can
be found in infected cells in the blood. However, HIV-1 can also establish reservoirs of
latently infected cells in several anatomical sites in the body, which are commonly known
as sanctuary sites.

During infection, suboptimal drug penetration at certain anatomical sites may contribute to
persistent HIV-1 replication and the replenishment of the latent reservoir 12. A number of
anatomical sites have been reported including: the gastrointestinal tract (GIT), the genital
tract, semen, lymphoid tissues (e.g. lymph nodes, spleen), and the brain/central nervous
system (CNS) 13–17. The CNS is an important anatomical reservoir of HIV-1 18. HIV-1 is
known to primarily infect macrophages and microglia cells in the CNS

12

. The

cerebrospinal fluid (CSF) also represents a separate compartment for HIV-1 replication 12.
The blood brain barrier separates the brain from the peripheral blood, and the bloodcerebrospinal fluid barrier restricts the movement of free molecules and cells into the CSF.
Both barriers provide obstacles for the passage of cART agents 12. Although cART reduces
HIV-1 in the CSF, viral genomes have been identified in the CSF, as well as in brain tissues
of infected individuals that were on suppressive cART

19,20

. This further suggest the

persistence of HIV-1 in the CNS. The GIT contains the largest amount of lymphoid tissues
and lymphocytes in the body

21

. Gut associated lymphoid tissues (GALT) are highly

targeted for infection and can maintain an elevated level of HIV-1 replication, which may
be related with the large proportion of activated T cells and high predominance of cells
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expressing the HIV-1 co-receptor CCR5

22

. Furthermore, the GIT harbors persistent

infections in individuals on long-term treatment, also making the GIT an important
anatomical site for HIV-1 persistence 23. HIV-1 has also been reported to infect cells of
the female and male genital tract 24. In the male genital tract, infections have been found in
T lymphocytes and macrophages isolated from semen. Lymphocytes and macrophages
infiltrating the testes, as well as spermatocytes, spermatids and residual germ cells can be
targeted by HIV-1

25,26

. Genital shedding of the virus has been observed in the semen

despite undetectable levels of viral RNA in the blood 26. Similarly, HIV-1 was detected in
multiple cells and tissues of the female genital tract, such as epithelial and stromal cells of
the uterus 27. Viral shedding from the genital tract has also been demonstrated in women
on cART 28. Lymphoid tissues such as the lymph nodes and the spleen are important sites
for viral infection and contain an abundance of infected cells. Despite a decrease in viral
RNA in the lymph nodes and spleen following cART, HIV-1 still persists in the lymph
nodes of infected people and in non-human primates on prolonged treatment 29–31.
cART distribution studies have shown variability in drug concentrations in certain
anatomical sites such as the CNS and lymph nodes compared to the peripheral blood.
These suboptimal concentrations contribute to the emergence of drug-resistant variants
within the anatomical reservoirs of individuals on treatment 32,33,34,31. Previous studies also
reported a significant difference in composition of drug-resistant variants within different
parts of GIT, such as the colon and the large intestine

35

. Overall, HIV-1 may be under

selective pressure leading to the evolution and emergence of distinct viral sequences in
sanctuary sites compared to those present in blood compartments. While viral variability
significantly affects pathogenesis and disease progression, little is known about the impact
of viral selective pressure on HIV-1 integration site distribution within anatomical sites as
other than peripheral blood. Integration is meditated by the viral integrase enzyme and is
an essential event in the life cycle of HIV-1 in which the viral genome is permanently
incorporated into the host genome. HIV-1 integration site distribution from peripheral
blood has been previously described

36,37

. Indeed, HIV-1 integration site selection from

peripheral blood studies is known to occur in transcriptionally active genes, which are rich
in GC and CpG islands content, high density of Alu repeat elements, low density in long
interspersed nuclear element (LINE) and DNaseI hypersensitive sites

38

. Moreover,
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integration also occurred in transcriptionally silent regions of the genome, such as gene
deserts, centromeric heterochromatin, satellite DNA, introns and alphoid repeats
39,40,41,36,37

.

Of importance, we previously identified non-B DNA structures as a novel factor that
influences HIV-1 integration during infection

41

. Non-B DNA motifs are secondary

structures that are abundant in our genome. They are formed by specific nucleotide
sequences that exhibit non-canonical DNA base pairing. Several of those motifs have been
identified. These include guanine-quadruplex (G4) motifs, A-phased repeats, inverted
repeats, direct repeats, cruciform, slipped motifs, mirror repeats, short-tandem repeats,
triplex repeats and Z-DNA. Latently infected cells with enriched integration near G4 and
Z-DNA motifs could not be reactivated by the αCD3/CD28 latency reversal agent (see
chapter 2). Since G4 and Z-DNA are known to suppress expression of adjacent genes, it
is possible that such structures can impact expression of adjacent proviruses

42, 43,44, 45

.

Furthermore, we have shown that different HIV-1 subtypes exhibit different integration
preferences for non-B DNA motifs, which are further altered by cART (see chapter 3).
We also previously determined the integration site selection in an HIV-1 vector based
system in murine brain cells 41. However, to our knowledge the integration site selection
of HIV-1 in compartmentalized sites from infected individuals has not been defined.
Moreover, most studies have assessed HIV-1 integration sites in peripheral blood

36,37

.

Findings from peripheral blood might not be observed in other body compartments,
particularly in lymphoid tissues of the GIT, where the frequency of infected cells is higher
46

, and the CNS and lymph nodes, where drug concentrations are lower compared to the

blood

18,33

. Since distinct HIV-1 strains can be found in compartmentalized sites in

comparison to those present in the peripheral blood during cART

35

, we analyzed HIV-1

integration site profile in different anatomical sites in the body. Our data showed that the
integration site profiles in the different anatomical sites are distinct, with striking
differences in preferences for G4 motifs.
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4.2
4.2.1

Materials and methods
Ethical statement and study participants’ information for
gastrointestinal tract biopsies samples and brain samples

Gastrointestinal tissue samples, peripheral blood mononuclear cells (PBMCs) and
peripheral blood lymphocytes (PBLs) (PBMCs/PBLs) for this study had been collected
from 5 infected individuals as previously described 35,47,48. Briefly, patients were enrolled
from a cohort of HIV-1 seropositive men who have sex with men (MSM). The cohort was
followed at the Southern Alberta Clinic (SAC), Calgary, Alberta from the year 1993 to
1996. Ethical approval for all protocols and procedures were obtained from the Conjoint
Health Ethics Research Board (CHREB, protocol approval #: REB15-1941) at the
University of Calgary and Alberta Health Services (Calgary). All patients signed an
informed consent upon enrollment. Patients were prospectively followed and testing for
plasma viral load and CD4+ T counts were performed for each individual at each visit.
Additionally, upper and lower gastrointestinal endoscopies were performed in order to
collect biopsies of tissues from the esophagus, stomach, duodenum, and colon. Samples
were cryopreserved during shipment and stored at -70°C within 1 hour of collection

47

.

PBMCs/PBLs were isolated from blood and stored in liquid nitrogen 35. This cohort was
recruited prior to the introduction of Highly Active Antiretroviral therapy
(HAART)/combination antiretroviral therapy (cART) at the SAC in late 1997. Samples
analyzed in this study were from individuals who received monotherapy, or dual therapy
with the nucleoside reverse transcriptase inhibitors (NRTIs) such as azidothymidine
(AZT/zidovudine), dideoxyinosine (ddI) or cART prior to the study and during the study
as previously described 35. Brain tissue samples used in this study have been collected from
the frontal lobe of 8 HIV-1 infected individuals as previously described 49. Samples were
collected at autopsy with appropriate consent and frozen at -80°C. Patients were not
receiving antiretroviral therapy at the time of samples collection.

4.2.2

DNA isolation and HIV-1 integration library

Total genomic DNA was extracted from gastrointestinal tract tissue biopsies and
(PBMCs/PBLs) using Trizol Reagent (Invitrogen) as described
extracted from brain tissues with Trizol Reagent.

35,47

. DNA was also
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All genomic DNAs were processed for integration site analysis and sequenced using the
Illumina MiSeq platform. Extracted genomic DNA was restriction enzyme digested with
MseI overnight at 37°C. Digested DNA was column purified with the Gel/PCR DNA
Fragments Kit (Geneaid, cat#: DF100) according to manufacturer’s instructions. Next,
compatible double-stranded linkers to the MseI sites were prepared as follows: MseI Linker
(+) 5’GTAATACGACTCACTATAGGGCTCCG CTTAAGGGAC 3’and MseI Linker (): 5’ [Phos]-TAGTCCCTTAAGCG GAG-[AmC7-Q] 3’ were mixed (20µl MseI Linker
(+) [40 µM] and 20 µl MseI Linker (-) [40 µM]). The linker mixture was denatured for 5
min at 90°C and cooled 1°C every 3 min until the temperature reached 20°C using the
T100TM Thermal Cycler (Bio-Rad). The prepared linkers from here on forward are referred
to as the “adapter mix”.
Purified DNA was linker ligated with the adapter mix at 21°C for about 14 hours with
13.5µl of MseI digested samples, 3.5µl of adapter mix, 1µl of T4 DNA Ligase (400U/µl,
[NEB, cat#: M0202S), and 2 µl of 10x ligase buffer. Subsequently, 20µl of the ligated
sample was digested at 37°C for 4 hours with 2µl of DpnI (20U/µl), 2µl of NarI (5U/µl),
5µl of 10x buffer and water to a total volume of 50µl. Following digestion, the samples
were column purified. The junctions between the integrated HIV-1 LTR sequence and
adjacent genomic sequence were amplified in two separate rounds of PCR amplification.
The HIV-1 NL4-3 LTR sequence were used to design primers that amplify through the
HIV-1 LTR. The RuparLTR (Forward) 5’-TGCTTCAAGTAGTGTGTGC-3’ primer that
anneals to the HIV-1 LTRs and the Linker1 (Reverse) 5’-GTAATACGACTCACTATAG
GGC-3’primer specific to the MseI linker sequences were used for the first round of PCR
amplification. Each PCR reaction mixture consisted of 15.5µl sterile water, 5µl of
NarI/DnpI digested sample, 2.5µl of 10x Advantage 2 PCR Buffer, 0.5 µl of 15µM of
Linker1 primer, 0.5 µl of 15µM RuparLTR primer, 0.5µl of 10mM dNTPs and 0.5 µl of
50X Advantage 2 PCR polymerase mix (Takara Bio Inc., cat#:639201). PCR was run on
T100TM Thermal Cycler (Bio-Rad) under the following cycling conditions: 1 min at 94°C,
5 cycles of 2 sec at 94°C, 1 min at 72°C with an additional 20 cycles of 2 sec at 94°C, 1
min at 67°C and a final extension cycle for 1 min at 72°C and a 4°C hold. The second
round of nested PCR amplification was performed using sample from the first round of

162

PCR amplification. The PCR reaction mixture and cycling condition were as described for
the first round of PRC amplification. The following primer set was used for nested PCR:
Rupar-LTR2nested

(Forward)

5’-CTCTGGTAACTAGAGATCCCTCAGAC

C-3’,

Linker2nested (Reverse) 5’-AGGGCTCCGCTTAAGGGAC-3’ and. Next, Illumina
adapter overhang nucleotide sequences were added to the HIV-1 LTR sequence and the
MseI linker sequence. Illutag-Forward 5’-GTCTCGTGGGCTCGGAGATGTGTATAA
GAGACAGCTCTGGTAACTAGAGATCCCTCAGAC C-3’and Illutag-Reverse 5’TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGGGCTCCGCTTAAGGGAC
-3’. Underlined section of the two Illutag primers represent the overhang section. Illumina
adapters were utilized in a PCR reaction mixture contained 15.5µl sterile water, 5µl of
nested PCR samples, 2.5µl of Advantage 2 PCR Buffer (10x), 0.5 µl of Forward adapter
(10µM), 0.5 µl of Reverse adapter (10µM), 0.5µl of dNTPs (10mM) and 0.5 µl of 50X
Advantage 2 PCR polymerase mix. PCR was run on T100TM Thermal Cycler (Bio-Rad).
Cycling conditions were as described for the first round of PRC amplification.
The PCR products were purified using AmPure XP beads (Beckman Coulter, cat#:
A63881) and the DNA samples were processed using the Nextera XT Index Kit (Illumina).
The Nextera XT Indexes technology utilizes a single tagmentation reaction that fragments
and tags input DNA with unique adapter and index (barcodes) sequences on both ends of
the DNA as previously described 41. . The DNA samples were purified using AmPure XP
beads following addition of the barcodes. The barcoded samples were quantified using the
Quant-it PicoGreen dsDNA Assay Kit (Invitrogen, cat#: P7589). The absorbance of the
samples were read (excitation 480nm for 10 sec and emission 540 nm for 10 sec) with the
Cytation5 Imaging Reader (BioTek) and the Gen5 3.02.1 analysis software. Sample
concentration was determined using a standard concentration curve. The barcoded samples
were sequenced through Illumina MiSeq using 2 × 150 bp chemistry at the London
Regional Genomics Centre at the Robarts Research Institute (Western University, Canada)
and at Case Western Reserve University (USA).

4.2.3

Integration site analysis

Fastq sequencing reads were quality trimmed and unique integration sites identified using
our in-house bioinformatics pipeline Barr Lab Integration Site Identification Pipeline
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(BLISIP) (version 2.9)

41

. BLISIP version 2.9 includes the following updates: bedtools

(v2.25.0) which is used to compute distances between integration sites and genomic
features, bioawk (awk version 20110810) a programming language for biological data
manipulation, bowtie2 (version 2.3.4.1) is used for aligning sequence reads to the human
genome, and restrSiteUtils (v1.2.9) is used to generate in silico matched random control
integration sites based on restriction enzyme used or DNA shearing method. HIV-1 LTRcontaining Fastq sequences were identified and filtered by allowing up to a maximum of
five mismatches with the reference NL4-3 LTR sequence and if the LTR sequence had no
match with any region of the human genome (GRCh37/hg19). Integration site profile
heatmaps were generated using our in-house python program BHmap (BHmap version
1.0). Sites that could not be unambiguously mapped to a single region in the genome were
excluded from the study. Mapping of integration sites to non-B DNA motifs was performed
using the Non-B DB for the human genome (GRCh37/hg19) as previously described 50, 51.
Lamina associated domains (LADs) were retrieved from http://dx.doi.org/10.1038/
nature06947 52.

4.2.4

Statistical analysis

The Fisher’s exact test was used for all comparisons of integration site distributions in
Figures 4.1, and 4.2. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

4.3
4.3.1

Results
HIV-1 anatomical reservoirs exhibit distinct integration site
preferences

To compare the integration site profiles in different anatomical sites in infected individuals,
we generated integration site libraries from genomic DNA isolated from tissues from the
blood (PBMCs/PBLs), esophagus, stomach, duodenum and colon of 5 HIV-1 infected
individuals receiving antiretroviral therapy (Supplemental Table 4.1). Integration sites
from brain samples were determined from a separate cohort of 8 HIV-1 infected individuals
who were not receiving antiretroviral therapy. To generate the integration site profile, we
used an in-house bioinformatics pipeline called BLISIP, as used previously (see chapters
2 and 3) and 41. Unique integration sites from each anatomical site were compared with
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matched random control (MRC) datasets generated in silico as previously described

41

.

The integration site distribution was divided into four bins starting from within each
genomic feature to > 50,000 base pairs (bp) away from the feature (Figure 4.1). In
agreement with the work presented in chapter 2 of this thesis and others 36, integration sites
in cells from our peripheral blood (PMBCs/PBLs) samples were enriched in genes (81%
of all integration sites) compared to MRC (Figure 4.1, Supplemental Table 4.2).
Integration sites in PBMCs/PBLs were also disfavored within CpG islands but highly
enriched near these genomic features. In the esophagus, stomach, duodenum, colon and
brain the majority of integration occurred within genes (79%, 71 %, 82%, 85% and 57%
respectively) similarly to PBMCs/PBLs. Interestingly, integration within genes was
drastically lower in brain samples compared to other tissues. Although all anatomical sites
exhibited enriched integration near CpG islands (5000-49999 bp; P < 0.001 or P < 0.0001)
including in PBMCs/PBLs, the duodenum also exhibited enrichment directly in CpG
islands compared to MRC (Figure 4.1). Additionally,

integration in or near

heterochromatic lamina-associated domains (LADs) and satellite DNA, which are
abundant in heterochromatin, were depleted in the brain as opposed to other reservoirs.
Together, these data show that our bioinformatics analyses agree with previous findings as
it related to integration sites in peripheral blood and shows that tissue from different
anatomical sites exhibit different preferences in their integration site selection.

4.3.2

Non-B DNA motifs are targeted for integration in different
anatomical reservoirs of HIV-1 infected individuals

Our previous findings showed that HIV-1 favors integration in and/or near non-B DNA
motifs in peripheral blood samples of infected individuals (see chapter 2 and 3). To assess
integration site frequency with respect to non-B DNA motifs in other anatomical reservoirs
(Supplemental Table 4.1) we quantified integration sites directly within each non-B DNA
motif or in distance bins of 50 bp up to 500 bp away from the feature. Integration analyses
were performed using BLISIP and unique integration sites were compared to the MRC. As
shown in Figure 4.2, the integration site profile differed considerably among the different
anatomical sites. The majority of integration sites were enriched directly in non-B DNA
motifs for PBMCs/PBLs, stomach and duodenum.
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Figure 4.1: HIV-1 anatomical reservoirs exhibit distinct integration site preferences.
Heatmap depicting the fold enrichment or depletion of integration sites in common
genomic features compared to the matched random control (MRC). Darker shades
represent higher fold-changes in the ratio of integration sites to MRC. Numbers within each
heatmap represent the fold-increase or decrease in the number of unique integration sites
in different anatomical reservoirs compared to MRC. With each heatmap, not a number
(nan) indicates that 0 integrations were observed and 0 were expected by chance.
Significant differences were determined by Fisher’s exact test and are denoted by asterisks
(*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Number of unique integration sites
are as follow: PBMCs/PBLs = 232 sites, esophagus = 255 sites, stomach = 308 sites,
duodenum = 195 sites, colon = 176 sites and the brain = 155 sites.
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Figure 4.1: HIV-1 anatomical reservoirs exhibit distinct integration site preferences.
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On the other hand, most integration occurred within 1-49 bp from non-B DNA in the colon.
Notably, integration in and/or near G4, Z-DNA, cruciform and triplex motifs was highly
enriched in the different anatomical reservoirs (Figure 4.2, Supplemental Table 4.3).
Interestingly, enriched integration 100-150 bp away from G4 was observed in all
anatomical reservoir as previous observed (see chapter 2 and 3). Additionally, integration
within cruciform motifs was only targeted in PBMCs/PBLs. Integration was also favored
near cruciform in PBMCs/PBLs. Other compartments (esophagus, stomach, colon,
duodenum and brain) showed enriched integration only near cruciform motifs. Compared
to other anatomical sites, the brain showed no preference for integration either in and/or
near triplex motifs. Together, these data identified distinct non-B DNA integration site
profiles for PBMCs/PBLs, colon, stomach, duodenum, esophagus and the brain.

4.4

Discussion

The data presented here show that different anatomical reservoirs of HIV-1 have different
integration site preferences. Importantly, we also identified integration to be enriched in or
near non-B DNA motifs in all anatomical reservoirs. Specifically, we determined that the
integration sites in all latent reservoirs are strongly enriched in or near specific non-B DNA
motifs that are known to inhibit gene expression, such as G4, cruciform, Z-DNA and triplex
structures

42,44,53–61

. Previous HIV-1 integration sites analyses in infected individuals

showed that active genes are preferred sites for integration in vivo. These datasets were
obtained from cells originating from peripheral blood (e.g. PBMCs or CD4 + T cells) 36,37.
In the current study, our analysis in PBMCs/PBLs of integration site distribution in genes
are consistent with other findings.
Integration site distribution in other anatomical reservoirs showed similar results as in the
peripheral blood except in the brain, which showed 15 to 28% lower frequency in genes
compared to other compartments. The lens epithelium derived growth factor and co-factor
p75 (LEDGF/p75) is a ubiquitously expressed protein which is well known to interact with
the viral integrase enzyme and help target integration into active genes of the genome. Even
though LEDGF/p75 is ubiquitously expressed, the expression of this protein is lower in the
adult human brain and within specific regions of the brain

62

.
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Figure 4.2: Non-B DNA motifs are targeted for integration in different anatomical
reservoirs of HIV-1 infected individuals. Heatmaps showing the distribution of unique
integration sites in non-B DNA motifs from PBMCs/PBLs, esophagus, stomach,
duodenum, colon and brain tissue samples compared to the matched random control
(MRC). Darker shades represent higher fold-changes in the ratio of integration sites to
MRC sites. Numbers within each heatmap represent the fold-increase or decrease in the
number of unique integration sites in different anatomical reservoir compared to MRC. Not
a number (nan) indicates that 0 integrations were observed and 0 were expected by chance.
Significant differences were determined by Fisher’s exact test and are denoted by asterisks
(*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Number of unique integration
sites are as follow: PBMC/PBL = 232 sites, esophagus = 255 sites, stomach = 308 sites,
duodenum = 195 sites, colon = 176 sites and the brain = 155 sites.
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Figure 4.2: Non-B DNA motifs that are for integration in different anatomical reservoirs of HIV-1 infected individuals.
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We and others also previously showed that depletion of LEDGF/p75 caused a substantial
decrease in integration into genes (chapter 2, Figure 2.3)

63,64,65,66

. The same was true for

the polyadenylation specificity factor 6 (CPSF6) protein which helps promote HIV-1
integration into actively transcribed genes residing in gene-dense regions, thereby reducing
integration into other genomic regions conducive to latency such as heterochromatin.
Therefore, a decreased expression of either LEDGF/p75 or CPSF6 may contribute to the
lower frequency of integration in genes seen in the brain compared to other anatomical
reservoirs. It is possible that the differences in integration are not only the result of selective
pressure of cART on the variability of HIV-1 sequences in different compartments, but the
result of the host cellular environment or the different phenotypes between the infected
cells in each compartment.
A recent study also showed that the transcriptional initiation in CD4+ T cells from the GIT
(e.g. rectum) is much lower than that of CD4+ T cells obtained from the blood 67. However,
it was unclear which cellular or viral factors contributed to the difference in transcriptional
repression within the two compartments. Given the ability of HIV-1 to target non-B DNA
motifs in the genome within different latent reservoirs, it is possible that the difference in
the transcriptional repression seen in compartments other than in the blood could be due to
their selective preferences in integration in or near specific non-B DNA motifs. Non-B
DNA are abundant in the human genome and have been associated with chromatin
remodeling and transcriptional activities

45

. It is possible that the expression of specific

host proteins influence HIV-1 site targeting into or near specific non-B DNA structures
within the different reservoirs.
In conclusion, our observations indicate that different anatomical reservoirs of HIV-1
infection are enriched in and/or near non-B DNA motifs and implicate non-B DNA motifs
as a potential factor influencing HIV-1 integration site targeting within various latent
reservoirs.
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Chapter 5

5

General discussion and future directions
5.1

Thesis summary

HIV-1 is the most clinically prevalent retrovirus in the human population that causes lifelong infection. The latent reservoir of HIV-1, which harbors transcriptionally silent
replication competent virus, represents the major obstacle for curing HIV-1 infection.
Although several bodies of work suggest that the integration site of the virus in the human
genome plays a critical role in disease persistence and reactivation of HIV-1 expression,
better understanding of the local genomic environment surrounding integrated proviruses
is needed to provide more insights into its contribution to latency. The work described in
my thesis presents my characterization of retroviral integration site selection and genomic
determinants that may impact latency establishment or reversal.
In Chapter 2 of this thesis, my work, and that of others in the laboratory, established a
strong correlation between HIV-1 integration sites in and/or near non-B DNA motifs and
latency. We were able to show that the location of integration sites that predominate in
latently infected cells are enriched in or near non-B DNA motifs, which are well-known to
inhibit gene expression. Specifically, we demonstrated that HIV-1 integration near
guanine-quadruplex (G4) motifs, a type of non-B DNA motif may influence reactivation
of the latent proviruses by latency reversal agents (Figure 2.2). To further characterize the
implication of G4 motifs in HIV-1 latency and integration site selection, we treated cells
with G4 ligands that stabilize or destabilize G4 structures, which were found to
significantly alter HIV-1 integration site preference for G4 motifs (Figure 2.5).
Historically, much of our understanding of HIV-1 infection has been primarily modeled on
HIV-1 subtype B infections. However, other subtypes exist around the world which are
known to present different disease progression as opposed to subtypes B 1. In Chapter 3, I
characterized the HIV-1 integration profiles of different HIV-1 subtypes via nextgeneration sequencing to determine if any difference exists in their integration site
selection preference. I also assessed the integration site profile among evolutionary diverse
retroviruses such as SIV, FIV, HTLV-1, MLV, MMTV, FV, ASLV and ERVs.
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Remarkably, our studies showed that non-B DNA motifs were highly targeted for
integration not only by HIV-1 subtype A, B, C and D but by other retroviruses (Figure 3.2
and 3.4 C). Antiretroviral treatment was shown to strongly alter the integration site profile
in different HIV-1 subtypes (Figure 3.6). Finally, in Chapter 4 I explored HIV-1
integration site preference in anatomical sites which are also known to harbor latent viruses
despite antiretroviral therapy. I utilized next generation sequencing to investigate the
difference in HIV-1 integration site selection in the peripheral blood, central nervous
system and gastrointestinal tract (GIT). Notably, we also showed here that non-B DNA
motifs are strongly targeted in different anatomical sites during infection. Interestingly, all
compartments also showed strong preferences for integration near G4 motifs (Figure 4.2).
Overall, we were able to expand our current understanding of HIV-1 integration site
preferences and identified non-B DNA motifs as novel factors that influence HIV-1
integration site targeting. Furthermore, we demonstrated that integration sites in latently
infected cells are enriched in and/or near non-B DNA motifs suggesting that non-B DNA
structures, particularly G4 motifs, likely contribute to the establishment and maintenance
of HIV-1 latency in subtypes B and in other subtypes.

5.1.1

Non-B DNA motifs are targeted in quiescent/latently infected
cells

Our analysis of HIV-1 integration site preference began through the assessment of viral
integration profile in latently infected cells from infected individuals. In our study, we
presented analyses that are consistent with previous studies showing that integration in
heterochromatin regions are more frequent in latently infected cells as opposed to
productively infected cells

2,3

(Figure 2.2). We also observed a strong enrichment of

integration near non-B DNA (e.g. G4 motifs) that strongly influence nearby gene
expression (Figure 2.1D and 2.2) and latency reactivation. Previous studies have shown
that G4 motifs are highly localized to heterochromatin 4. The fact that integration sites in
or near G4-motifs were strongly enriched in latently infected cells could further explain
why heterochromatin regions are targeted in latently infected cells. Alternatively, G4 motif
binding proteins might influence integration near these motifs. This could also be the case
for other non-B DNA motifs. Interestingly, HIV-1 integrase is known to bind directly to
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G4 motifs 5–14. Other tethering factors such LEDGF/p75 and CPSF6 have been shown to
promote integration into euchromatin regions, which are more permissive for gene
expression. In our present study, we have showed that LEDGF/p75 and CPSF6 promote
integration in and/or near non-B DNA motifs, especially those known to repress gene
expression (e.g. G4, Z-DNA, cruciform and triplex motifs) (Figure 2.3).
Latency reversal agents have been proposed to reactivate the latent reservoir and induce
depletion of the virus

15

. However, only a small fraction of the latent reservoir can be

reactivated 3,16. It is therefore conceivable that the integration site placement within certain
genomic features contribute to the maintenance and establishment of the latent reservoir.
In this thesis we further demonstrated that failure to become reactivated by latency reversal
agent (αCD3/CD28) correlated with HIV-1 integration near non-B DNA motifs
particularly G4, and Z-DNA motifs (Figure 2.2). Since G4 motifs and Z-DNA are known
to both impede nearby gene expression though mechanisms that involve stalling of the
RNA polymerase or interfering with the assembly of transcription pre-initiation complexes
17,18 17–19

it is possible that integration near non-B DNA motifs can significantly silence

proviral expression therefore contributing to latency. Our findings using G4-stabilizing
and G4-destabilizing ligands to modulate G4 formation indicate that the secondary
structure of non-B DNA motifs and not their primary sequences is more likely to play an
important role in attracting HIV-1 pre-integration complex (Figure 2.5).

5.1.2

A comparative analysis of the integration site distribution of
evolutionary diverse retroviruses

Different HIV-1 subtypes are known to present different disease progression. Integration
which is an important event in the life cycle of retroviruses is essential for replication to
occur. We therefore explored the differences in integration profile among different HIV-1
subtypes and evolutionary diverse retroviruses. Interestingly, we showed that non-B DNA
motifs are also targeted by other retroviruses. However, they presented distinct integration
profiles (Figure 3.2). Variations in the properties of their integrase proteins could greatly
influence their integration site targeting. Furthermore, sequence differences in their
integrase gene could also influence their integration site preference for specific genomic
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features. Interaction of the virus with cellular host factors and chromosomal DNA might
also be essential in determining proviral integration site selection.
In another series of experiments, we further dissected the differences in integration profile
seen in in vitro infection models of HIV-1 and datasets from infected individuals. Here we
showed profound differences in integration site targeting preferences between in vitroderived and patient-derived integration site datasets. Notably, enrichment of HIV-1
integration in and/or near non-DNA motifs that potentially regulate gene expression, such
as G4 motifs, is observed in patient derived data (Figure 3.3). Interestingly our data also
showed similar integration preference with respect to commonly studied genomic features
such as genes, CpG islands, satellite DNA and LADs among subtypes A, B, C and D
(Figure 3.4 A, and B). However, substantial differences were observed among the
different subtypes with respect to non-B DNA motifs (Figure 3.4 C). Notably, subtype B
is the only subtype that showed enriched integration within specific distances from non-B
DNA motifs (between 150-500 bp). It remains unclear why subtype B is the only subtype
that showed enriched integration within specific distances from non-B DNA compared to
other subtypes. Differences in the integrase structure of each subtype could contribute to
this difference in integration. Natural polymorphisms in HIV-1 integrase have been
observed among different subtypes, which might affect their integration site selection 20,21.
Additionally specific polymorphisms in HIV-1 integrase have been reported to retarget
integration away from gene dense regions, which correlated with increase disease
progression and virulence

22

. This further suggest that viral integrase can substantially

contribute to disease progression, as it is related to the virus integration site.

5.1.3

Combination antiretroviral therapy (cART) alters HIV-1
integration site selection

cART helps select for integration into silent regions such as intergenic regions that can
maintain latency 23. We further investigated the association between treatment and HIV-1
integration site selection among different HIV-1subtypes. Our observations indicate that
cART changed the integration profile for all subtypes with respect to common genomic
features and non-B DNA motifs (Figure 3.5 and 3.6). Our data showed integration
enrichment in heterochromatin rich region such as LAD regions, in treated individuals
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compared to untreated individuals of subtype A, B and D infections (Figure 3.5). This
further confirms that cART selects for cells harboring integration sites in heterochromatin
among different subtypes. Additionally, cART led to enriched integration near G4 motifs,
which are also found in heterochromatin rich regions 4.

5.1.4

Non-B DNA motifs influence HIV-1 integration in anatomical
reservoirs

Besides peripheral blood, which is the most studied anatomical site for HIV-1 infection,
other anatomical sites are also known to harbor latent virus during HIV-1 infection 24,25, 26,
27, 28, 29–31

. In this final study, our integration site distribution analysis across anatomical

sites such as in PBMCs/ PBLs, GIT (esophagus, colon, duodenum and stomach) and brain
revealed that other anatomical sites showed similar integration level in genes as in the
peripheral blood except in the brain which showed drastically reduced integration within
genes (Figure 4.1). This difference in integration into genes could be due to the lower
expression of host cellular factors known to target integration into transcriptionally active
genes such as LEDGF/p75 and CPSF6 the in the brain. In fact, LEDGF/p75 expression is
slightly lower in the adult human brain and within specific regions of the brain

32

.

Expression levels of CPSF6 is thought to be highly expressed in the brain and the stomach.
Additionally, integration in and/or near non-B DNA motifs (e.g. G4, Z-DNA, cruciform
and triplex motifs) that are known to suppress gene expression were strongly targeted in
the different anatomical reservoirs (Figure 4.2)

33,18,34,19,35–39,17,40

. It is possible that the

expression of specific host proteins influence HIV-1 site targeting into or near specific nonB DNA structures within these different reservoirs.
Throughout this study, enriched HIV-1 integration at intervals of 100-149bp away from
G4 motifs was consistently observed. The ability of HIV-1 to integrate at that specific
distance could be the results of non-B DNA inducing repositioning of nucleosomes, which
are comprised of ~147 bp of DNA wrapped around a histone octamer core 41. In fact, G4
motifs are known to form in nucleosome-free regions in the genome and their ability to
dynamically organize flanking nucleosomes may contribute to transcriptional regulation of
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integrated proviruses and potentially cause a transcriptional block of proviral gene
expression 42.

5.2

Future directions

Latency is a major obstacle to a functional cure. In this work we have shown that G4 motifs
are strongly targeted for integration during latent infection, which is important as they are
known to impede adjacent gene expression. These motifs were shown to correlate with the
failure of latency reversal agents (Figure 2.2B). We have also demonstrated that
compounds either stabilizing or destabilizing G4 alter HIV-1 integration profile with
respect to G4 (Figure 2.5). It will be important to further assess whether these compounds
(BRACO19 and TMPyP4) can enhance or lower the activity of latency reversal agents and
proviral gene expression. This could be tested in vitro by using a dual color reporter as
described in Chapter 2, section 2.3.2 to establish the percent of latently reactivated cells
following treatment with these compounds. Additional, the synergetic effect of these G4
compounds and currently used latency reversal agents could be tested to determine whether
this will induce a substantial reactivation of latently infected cells.
To further assess the implication of G4 on gene expression and how this might also affect
proviral gene expression, G4 sequence motifs could be cloned either upstream or
downstream of a promoter site in a luciferase construct containing HIV-1 LTR where
luciferase expression will be determined.
The integrase protein is essential for HIV-1 infection. Another study that could be
performed would be to determine the sequence variation among different HIV-1 to
determine how specific changes might correlate to the differences seen in their integration
profiles that we observed. Experiments involving switching the integrase sequence of HIV1 and other retroviruses will further help assess the differences in integration profile seen
among evolutionary diverse retroviruses.

5.3

Concluding remarks and significance

HIV-1 persistence from latency presents a major barrier for eradication and a functional
cure. This is in part due to the slow decay of the latent reservoir (which has an estimated
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half-life of 44 months

43,44

). Advances in the development of cART help control HIV-1

replication in infected individuals, but fail to eradicate this latent pool. In fact, it has been
calculated that it would take more than 70 years to eradicate HIV-1 under cART treatment.
The long-term goal of this study is to characterize and further understand the implication
of HIV-1 integration site selection on latency. Our study has provided novel insight into
the role of HIV-1 integration site selection and it potential contribution to latency.
Specifically, we identified non-B DNA motifs to be a novel factor that could substantially
contribute to HIV-1 persistence/latency and integration site selection. With this work, we
hope to help inform the design of future experiments in HIV-1 eradication research and in
designing better gene therapy vectors based on HIV-1 biology.
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